

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/005216

International filing date: 17 February 2005 (17.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/545,292
Filing date: 18 February 2004 (18.02.2004)

Date of receipt at the International Bureau: 17 March 2005 (17.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1294347

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 09, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/545,292

FILING DATE: February 18, 2004

RELATED PCT APPLICATION NUMBER: PCT/US05/05216



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office



17224 U.S. PTO

Atty. Dkt. No. 085747-0325

322782 U.S. PTO
60/545292



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jalaj Arora et al.

Title: *POLY-HETEROCYCLIC COMPOUNDS AND THEIR USE AS
METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS*

Appl. No.: Unassigned

Filing Date: February 18, 2004

PROVISIONAL PATENT APPLICATION
TRANSMITTAL

Mail Stop PROVISIONAL PATENT APPLICATION
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(c) is the provisional patent application of:

Jalaj ARORA
Louise EDWARDS
Methvin ISAAC
Annika KERS
Karin OSCARSSON
Abdelmalik SLASSI
Tomislav STEFANEC
David WENSBO
Tao XIN

☐ Applicant claims small entity status under 37 CFR 1.27(c)(1).

Enclosed are:

☒ Specification, Claim(s), and Abstract (71 pages).

☐ Assignment of the invention to AstraZeneca and NPS Pharmaceuticals, Inc..

☒ Application Data Sheet (37 CFR 1.76).

The filing fee is calculated below:

	Rate	Fee Totals
Basic Fee	\$160.00	\$160.00
Surcharge under 37 CFR 1.16(e) for late payment of filing fee	+ \$50.00 =	\$50.00
	SUBTOTAL: =	\$210.00
[] Small Entity Fees Apply (subtract ½ of above):	=	\$0.00
	TOTAL FILING FEE: =	\$210.00

- [] A check in the amount of \$0.00 to cover the filing fee is enclosed.
- [X] The required filing fees are not enclosed but will be submitted in response to the Notice to File Missing Parts of Application.
- [X] Further, Applicant, by and through his attorney of record, hereby expressly abandons the application as of the filing date of this letter. This is an abandonment of the application only, and is not to be construed as an abandonment of the invention disclosed in the application. It is respectfully requested that the Office acknowledge abandonment of the application as of the filing date of this letter in a communication mailed to the undersigned.
- [] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date 18 February 2004

FOLEY & LARDNER
 Customer Number: 22428
 Telephone: (202) 672-5404
 Facsimile: (202) 672-5399

By S. A. Bent

Stephen A. Bent
 Attorney for Applicant
 Registration No. 29,768

POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

FIELD OF THE INVENTION

The present invention relates to a new class of compounds, to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy. The present invention further relates to processes for the preparation of said compounds and to new intermediates used in the preparation thereof.

BACKGROUND OF THE INVENTION

Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS). Glutamate produces its effects on central neurons by binding to and thereby activating cell surface receptors. These receptors have been divided into two major classes, the ionotropic and metabotropic glutamate receptors, based on the structural features of the receptor proteins, the means by which the receptors transduce signals into the cell, and pharmacological profiles.

The metabotropic glutamate receptors (mGluRs) are G protein-coupled receptors that activate a variety of intracellular second messenger systems following the binding of glutamate. Activation of mGluRs in intact mammalian neurons elicits one or more of the following responses: activation of phospholipase C; increases in phosphoinositide (PI) hydrolysis; intracellular calcium release; activation of phospholipase D; activation or inhibition of adenylyl cyclase; increases or decreases in the formation of cyclic adenosine monophosphate (cAMP); activation of guanylyl cyclase; increases in the formation of cyclic guanosine monophosphate (cGMP); activation of phospholipase A₂; increases in arachidonic acid release; and increases or decreases in the activity of voltage- and ligand-gated ion channels. Schoepp *et al.*, *Trends Pharmacol. Sci.* 14:13 (1993), Schoepp, *Neurochem. Int.* 24:439 (1994), Pin *et al.*, *Neuropharmacology* 34:1 (1995), Bordi and

Ugolini, *Prog. Neurobiol.* 59:55 (1999).

Eight distinct mGluR subtypes, termed mGluR1 through mGluR8, have been identified by molecular cloning. Nakanishi, *Neuron* 13:1031 (1994), Pin *et al.*, *Neuropharmacology* 34:1 (1995), Knopfel *et al.*, *J. Med. Chem.* 38:1417 (1995). Further receptor diversity occurs via expression of alternatively spliced forms of certain mGluR subtypes. Pin *et al.*, *PNAS* 89:10331 (1992), Minakami *et al.*, *BBRC* 199:1136 (1994), Joly *et al.*, *J. Neurosci.* 15:3970 (1995).

Metabotropic glutamate receptor subtypes may be subdivided into three groups, Group I, Group II, and Group III mGluRs, based on amino acid sequence homology, the second messenger systems utilized by the receptors, and by their pharmacological characteristics. Group I mGluR comprises mGluR1, mGluR5 and their alternatively spliced variants. The binding of agonists to these receptors results in the activation of phospholipase C and the subsequent mobilization of intracellular calcium.

Neurological, psychiatric and pain disorders.

Attempts at elucidating the physiological roles of Group I mGluRs suggest that activation of these receptors elicits neuronal excitation. Various studies have demonstrated that Group I mGluRs agonists can produce postsynaptic excitation upon application to neurons in the hippocampus, cerebral cortex, cerebellum, and thalamus, as well as other CNS regions. Evidence indicates that this excitation is due to direct activation of postsynaptic mGluRs, but it also has been suggested that activation of presynaptic mGluRs occurs, resulting in increased neurotransmitter release. Baskys, *Trends Pharmacol. Sci.* 15:92 (1992), Schoepp, *Neurochem. Int.* 24:439 (1994), Pin *et al.*, *Neuropharmacology* 34:1(1995), Watkins *et al.*, *Trends Pharmacol. Sci.* 15:33 (1994).

Metabotropic glutamate receptors have been implicated in a number of normal processes in the mammalian CNS. Activation of mGluRs has been shown to be required for induction of hippocampal long-term potentiation and cerebellar long-term depression. Bashir *et al.*, *Nature* 363:347 (1993), Bortolotto *et al.*, *Nature* 368:740 (1994), Aiba *et al.*, *Cell* 79:365 (1994), Aiba *et al.*, *Cell* 79:377 (1994). A role for mGluR activation in nociception and analgesia also has been demonstrated. Meller *et al.*, *Neuroreport* 4: 879 (1993), Bordi and Ugolini, *Brain Res.* 871:223 (1999). In addition, mGluR activation has been suggested to

play a modulatory role in a variety of other normal processes including synaptic transmission, neuronal development, apoptotic neuronal death, synaptic plasticity, spatial learning, olfactory memory, central control of cardiac activity, waking, motor control and control of the vestibulo-ocular reflex. Nakanishi, *Neuron* 13: 1031 (1994), Pin *et al.*, *Neuropharmacology* 34:1, Knopfel *et al.*, *J. Med. Chem.* 38:1417 (1995).

Further, Group I metabotropic glutamate receptors have been suggested to play roles in a variety of acute and chronic pathophysiological processes and disorders affecting the CNS. These include stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, epilepsy, neurodegenerative disorders such as Alzheimer's disease, psychiatric disorders and pain. Schoepp *et al.*, *Trends Pharmacol. Sci.* 14:13 (1993), Cunningham *et al.*, *Life Sci.* 54:135 (1994), Hollman *et al.*, *Ann. Rev. Neurosci.* 17:31 (1994), Pin *et al.*, *Neuropharmacology* 34:1 (1995), Knopfel *et al.*, *J. Med. Chem.* 38:1417 (1995), Spooren *et al.*, *Trends Pharmacol. Sci.* 22:331 (2001), Gasparini *et al.*, *Curr. Opin. Pharmacol.* 2:43 (2002), Neugebauer *Pain* 98:1 (2002). Much of the pathology in these conditions is thought to be due to excessive glutamate-induced excitation of CNS neurons. Because Group I mGluRs appear to increase glutamate-mediated neuronal excitation via postsynaptic mechanisms and enhanced presynaptic glutamate release, their activation probably contributes to the pathology. Accordingly, selective antagonists of Group I mGluR receptors could be therapeutically beneficial in all conditions underlain by excessive glutamate-induced excitation of CNS neurons, specifically as neuroprotective agents, analgesics or anticonvulsants.

Recent advances in the elucidation of the neurophysiological roles of metabotropic glutamate receptors generally and Group I in particular, have established these receptors as promising drug targets in the therapy of acute and chronic neurological and psychiatric disorders and chronic and acute pain disorders.

Gastro intestinal disorders

The lower esophageal sphincter (LES) is prone to relaxing intermittently. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical barrier is temporarily lost at such times, an event hereinafter referred to as "G.I. reflux".

Gastro-esophageal reflux disease (GERD) is the most prevalent upper gastrointestinal tract disease. Current pharmacotherapy aims at reducing gastric acid secretion, or at neutralizing acid in the esophagus. The major mechanism behind G.I. reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, e.g. *Holloway & Dent (1990) Gastroenterol. Clin. N. Amer. 19, pp. 517-535*, has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESRs), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD.

The novel compounds according to the present invention are assumed to be useful for the inhibition of transient lower esophageal sphincter relaxations (TLESRs) and thus for treatment of gastro-esophageal reflux disorder (GERD).

The wording "TLESR", transient lower esophageal sphincter relaxations, is herein defined in accordance with *Mittal, R.K., Holloway, R.H., Penagini, R., Blackshaw, L.A., Dent, J., 1995; Transient lower esophageal sphincter relaxation. Gastroenterology 109, pp. 601-610*.


The wording "G.I. reflux" is herein defined as fluid from the stomach being able to pass into the esophagus, since the mechanical barrier is temporarily lost at such times.

The wording "GERD", gastro-esophageal reflux disease, is herein defined in accordance with *van Heerwarden, M.A., Smout A.J.P.M., 2000; Diagnosis of reflux disease. Baillière's Clin. Gastroenterol. 14, pp. 759-774*.

Because of their physiological and pathophysiological significance, there is a need for new potent mGluR agonists and antagonists that display a high selectivity for mGluR subtypes, particularly the Group I receptor subtype.

SUMMARY OF THE INVENTION

In one aspect of the invention there is provided a compound according to formula I



Formula I

wherein

P is selected from aryl and heteroaryl;

R^1 is attached to P via a carbon atom on ring P and is selected from the group consisting of: hydroxy, halo, nitro, C_{1-6} alkylhalo, OC_{1-6} alkylhalo, C_{1-6} alkyl, OC_{1-6} alkyl, C_{2-6} alkenyl, OC_{2-6} alkenyl, C_{2-6} alkynyl, OC_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, OC_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylaryl, OC_{0-6} alkylaryl, CHO, $(CO)R^5$, $O(CO)R^5$, $O(CO)OR^5$, $O(CNR^5)OR^5$, C_{1-6} alkyl OR^5 , OC_{2-6} alkyl OR^5 , C_{1-6} alkyl $(CO)R^5$, OC_{1-6} alkyl $(CO)R^5$, C_{0-6} alkyl CO_2R^5 , OC_{1-6} alkyl CO_2R^5 , C_{0-6} alkylcyano, OC_{2-6} alkylcyano, C_{0-6} alkyl NR^5R^6 , OC_{2-6} alkyl NR^5R^6 , C_{1-6} alkyl $(CO)NR^5R^6$, OC_{1-6} alkyl $(CO)NR^5R^6$, C_{0-6} alkyl $NR^5(CO)R^6$, OC_{2-6} alkyl $NR^5(CO)R^6$, C_{0-6} alkyl $NR^5(CO)NR^5R^6$, C_{0-6} alkyl SR^5 , OC_{2-6} alkyl SR^5 , C_{0-6} alkyl $(SO)R^5$, OC_{2-6} alkyl $(SO)R^5$, C_{0-6} alkyl SO_2R^5 , OC_{2-6} alkyl SO_2R^5 , C_{0-6} alkyl $(SO_2)NR^5R^6$, OC_{2-6} alkyl $(SO_2)NR^5R^6$, C_{0-6} alkyl $NR^5(SO_2)R^6$, OC_{2-6} alkyl $NR^5(SO_2)R^6$, C_{0-6} alkyl $NR^5(SO_2)NR^5R^6$, OC_{2-6} alkyl $NR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $O(CO)NR^5R^6$, NR^5OR^6 , C_{0-6} alkyl $NR^5(CO)OR^6$, OC_{2-6} alkyl $NR^5(CO)OR^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

X^1 is selected from the group consisting of: N, NR^4 and CR^4 ;

X^2 is selected from the group consisting of: C and N;

X^3 is selected from the group consisting of: CR^4 , N and O;

$\text{alkyl}(\text{SO}_2)\text{R}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{OC}_{2-6}\text{alkyl}(\text{SO})\text{R}^5$ and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R^5 and R^6 are independently selected from, H, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-7}\text{cycloalkyl}$ and aryl;

m is selected from 0, 1, 2, 3 or 4;

n is selected from 0, 1, 2, 3 or 4;

p is selected from 0, 1, 2, 3 or 4; and

a salt or hydrate thereof.

In a further aspect of the invention there is provided pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula I and a pharmaceutically acceptable diluent, excipients and/or inert carrier.

In yet a further aspect of the invention there is provided a pharmaceutical composition comprising a compound of formula I for use in the treatment of mGluR 5 receptor mediated disorders, and for use in the treatment of neurological disorders, psychiatric disorders, gastrointestinal disorders and pain disorders.

In still a further aspect of the invention there is provided the compound of formula I for use in therapy, especially for the treatment of mGluR 5 receptor mediated disorders, and for the treatment of neurological disorders, psychiatric disorders, gastrointestinal disorders and pain disorders.

In another aspect of the invention there is provided processes for the preparation of compounds of formula I and the intermediates used in the preparation thereof.

These and other aspects of the present invention are described in greater detail herein below.

DETAILED DESCRIPTION OF THE INVENTION

The object of the present invention is to provide compounds exhibiting an activity at metabotropic glutamate receptors (mGluRs), especially at the mGluR 5 receptors.

Listed below are definitions of various terms used in the specification and claims to describe the present invention.

For the avoidance of doubt it is to be understood that where in this specification a group is qualified by 'hereinbefore defined', 'defined hereinbefore' or 'defined above' said group encompasses the first occurring and broadest definition as well as each and all of the other definitions for that group.

For the avoidance of doubt it is to be understood that in this specification 'C₁₋₆' means a carbon group having 1, 2, 3, 4, 5 or 6 carbon atoms. Similarly 'C₁₋₃' means a carbon group having 1, 2, or 3 carbon atoms

In the case where a subscript is the integer 0 (zero) the group to which the subscript refers indicates that the group is absent.

In this specification, unless stated otherwise, the term "alkyl" includes both straight and branched chain alkyl groups and may be, but are not limited to methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl or i-hexyl, t-hexyl. The term C₁₋₃alkyl has 1 to 3 carbon atoms and may be methyl, ethyl, n-propyl or i-propyl.

In this specification, unless stated otherwise, the term "cycloalkyl" refers to an optionally substituted, saturated cyclic hydrocarbon ring system. The term "C₃₋₇cycloalkyl" may be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

In this specification, unless stated otherwise, the term “alkoxy” includes both straight or branched alkoxy groups. C₁₋₃alkoxy may be, but is not limited to methoxy, ethoxy, n-propoxy or i-propoxy.

In this specification, unless stated otherwise, the term “bond” may be a saturated or unsaturated bond.

In this specification, unless stated otherwise, the term “halo” and “halogen” may be fluoro, chloro, bromo or iodo.

In this specification, unless stated otherwise, the term “alkylhalo” means an alkyl group as defined above, which is substituted with halo as described above. The term “C₁₋₆alkylhalo” may include, but is not limited to fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl or bromopropyl. The term “OC₁₋₆alkylhalo” may include, but is not limited to fluoromethoxy, difluoromethoxy, trifluoromethoxy, fluoroethoxy or difluoroethoxy.

In this specification, unless stated otherwise, the term “alkenyl” includes both straight and branched chain alkenyl groups. The term “C₂₋₆alkenyl” refers to an alkenyl group having 2 to 6 carbon atoms and one or two double bonds, and may be, but is not limited to vinyl, allyl, propenyl, i-propenyl, butenyl, i-butenyl, crotyl, pentenyl, i-pentenyl and hexenyl.

In this specification, unless stated otherwise, the term “alkynyl” includes both straight and branched chain alkynyl groups. The term C₂₋₆alkynyl having 2 to 6 carbon atoms and one or two triple bonds, and may be, but is not limited to ethynyl, propargyl, butynyl, i-butynyl, pentynyl, i-pentynyl and hexynyl.

In this specification unless otherwise stated the term “aryl” refers to an optionally substituted monocyclic or bicyclic hydrocarbon ring system containing at least one unsaturated aromatic ring. Examples and suitable values of the term “aryl” are phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, indyl and indenyl.

In this specification, unless stated otherwise, the term “heteroaryl” refers to an optionally substituted monocyclic or bicyclic unsaturated, ring system containing at least one heteroatom selected independently from N, O or S. Examples of “heteroaryl” may be, but are not limited to thiophene, thienyl, pyridyl, thiazolyl, furyl, pyrrolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolonyl, oxazolonyl, thiazolonyl, tetrazolyl and thiadiazolyl, benzoimidazolyl, benzooxazolyl, tetrahydrotriazolopyridyl, tetrahydrotriazolopyrimidinyl, benzofuryl, indolyl, isoindolyl, pyridonyl, pyridazinyl, pyrimidinyl, imidazopyridyl, oxazolopyridyl, thiazolopyridyl, pyridyl, imidazopyridazinyl, oxazolopyridazinyl, thiazolopyridazinyl and purinyl.

In this specification, unless stated otherwise, the term “alkylaryl”, “alkylheteroaryl ” and “alkylcycloalkyl ” refer to a substituent that is attached via the alkyl group to an aryl, heteroaryl and cycloalkyl group.

In this specification, unless stated otherwise, the term “heterocycloalkyl” refers to an optionally substituted, saturated cyclic hydrocarbon ring system wherein one or more of the carbon atoms are replaced with heteroatom. The term “heterocycloalkyl” includes but is not limited to pyrrolidine, tetrahydrofuran, tetrahydrothiophene, piperidine, piperazine, morpholine, thiomorpholine, tetrahydropyran, tetrahydrothiopyran.

In this specification, unless stated otherwise the term “5- or 6-membered ring containing atoms independently selected from C, N, O or S”, includes aromatic and heteroaromatic rings as well as carbocyclic and heterocyclic rings, which may be saturated, partially saturated or unsaturated. Examples of such rings may be, but are not limited to furyl, isoxazolyl, isothiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, imidazolidinyl, imidazolinyl, triazolyl, morpholinyl, piperazinyl, piperidyl, piperidonyl, pyrazolidinyl, pyrazolinyl, pyrrolidinyl, pyrrolinyl, tetrahydropyranyl, thiomorpholinyl, phenyl, cyclohexyl, cyclopentyl and cyclohexenyl.


In this specification, unless stated otherwise, the term “=NR⁵” and “=NOR⁵” include imino- and oximogroups carrying an R⁵ substituent and may be, or be part of, groups including, but not limited to iminoalkyl, iminohydroxy, iminoalkoxy, amidine, hydroxyamidine and alkoxyamidine.

In the case where a subscript is the integer 0 (zero) the group to which the subscript refers, indicates that the group is absent, i.e. there is a direct bond between the groups.

In this specification unless stated otherwise the term “fused rings” refers to two rings which share 2 common atoms.

In this specification, unless stated otherwise, the term “bridge” means a molecular fragment, containing one or more atoms, or a bond, which connects two remote atoms in a ring, thus forming either bi- or tricyclic systems.

One embodiment of the invention relates to compounds of Formula I



Formula I

wherein

P is selected from aryl and heteroaryl;

R¹ is attached to P via a carbon atom on ring P and is selected from the group consisting of : hydroxy, halo, nitro, C₁₋₆alkylhalo, OC₁₋₆alkylhalo, C₁₋₆alkyl, OC₁₋₆alkyl, C₂₋₆alkenyl, OC₂₋₆alkenyl, C₂₋₆alkynyl, OC₂₋₆alkynyl, C₀₋₆alkylC₃₋₆cycloalkyl, OC₀₋₆alkylC₃₋₆cycloalkyl, C₀₋₆alkylaryl, OC₀₋₆alkylaryl, CHO, (CO)R⁵, O(CO)R⁵, O(CO)OR⁵, O(CNR⁵)OR⁵, C₁₋₆alkylOR⁵, OC₂₋₆alkylOR⁵, C₁₋₆alkyl(CO)R⁵, OC₁₋₆alkyl(CO)R⁵, C₀₋₆alkylCO₂R⁵, OC₁₋₆alkylCO₂R⁵, C₀₋₆alkylcyano, OC₂₋₆alkylcyano, C₀₋₆alkylNR⁵R⁶, OC₂₋₆alkylNR⁵R⁶, C₁₋

$_6\text{alkyl}(\text{CO})\text{NR}^5\text{R}^6$, $\text{OC}_{1-6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{CO})\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{NR}^5\text{R}^6$, $\text{C}_{0-6}\text{alkylSR}^5$, $\text{OC}_{2-6}\text{alkylSR}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{OC}_{2-6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{C}_{0-6}\text{alkylSO}_2\text{R}^5$, $\text{OC}_{2-6}\text{alkylSO}_2\text{R}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2-6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $(\text{CO})\text{NR}^5\text{R}^6$, $\text{O}(\text{CO})\text{NR}^5\text{R}^6$, NR^5OR^6 , $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

X^1 is selected from the group consisting of: N, NR^4 and CR^4 ;

X^2 is selected from the group consisting of: C and N;

X^3 is selected from the group consisting of: CR^4 , N and O;

X^4 is selected from the group consisting of: CR^4 , N, NR^4 and O;

X^5 is selected from the group consisting of: a bond, $\text{CR}^4\text{R}^{4'}$, NR^4 , O, S, SO and SO_2 ;

X^6 is selected from the group consisting of: CR^4 and N;

X^7 is selected from the group consisting of: C and N;

R^4 is independently selected from a group consisting of hydrogen, hydroxy, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{0-6}\text{alkylcyano}$, oxo, $=\text{NR}^5$, $=\text{NOR}^5$, $\text{C}_{1-4}\text{alkylhalo}$, halo, $\text{C}_{3-7}\text{cycloalkyl}$, $\text{O}(\text{CO})\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkyl}(\text{SO})\text{C}_{0-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkyl}(\text{SO}_2)\text{C}_{0-4}\text{alkyl}$, $(\text{SO})\text{C}_{0-4}\text{alkyl}$, $(\text{SO}_2)\text{C}_{0-4}\text{alkyl}$, $\text{OC}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylOR}^5$ and $\text{C}_{0-4}\text{alkylNR}^5\text{R}^6$;

Q is selected the group consisting of heterocycloalkyl and heteroaryl;

R^2 and R^3 are independently selected from the group consisting of: hydroxy, $\text{C}_{0-6}\text{alkylcyano}$, oxo, $=\text{NR}^5$, $=\text{NOR}^5$, $\text{C}_{1-4}\text{alkylhalo}$, halo, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{0-6}\text{alkylaryl}$, $\text{C}_{0-6}\text{alkylheteroaryl}$, $\text{C}_{1-6}\text{alkylcycloalkyl}$, $\text{C}_{0-6}\text{alkylheterocycloalkyl}$, $\text{OC}_{1-4}\text{alkyl}$, $\text{OC}_{0-6}\text{alkylaryl}$, $\text{O}(\text{CO})\text{C}_{1-4}\text{alkyl}$, $(\text{CO})\text{OC}_{1-4}\text{alkyl}$, $\text{C}_{0-4}\text{alkyl}(\text{S})\text{C}_{0-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkyl}(\text{SO})\text{C}_{0-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkyl}(\text{SO}_2)\text{C}_{0-4}\text{alkyl}$, $(\text{SO})\text{C}_{0-4}\text{alkyl}$, $(\text{SO}_2)\text{C}_{0-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylOR}^5$, $\text{C}_{0-4}\text{alkylNR}^5\text{R}^6$ and a 5- or 6-membered ring containing atoms independently selected from C, N, O and S, which ring may optionally be fused with a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N and O and wherein said

ring and said fused ring may be substituted by one or more A;

wherein any C₁₋₆alkyl, aryl, or heteroaryl defined under R¹, R² and R³ may be substituted by one or more A ;

A is selected from the group consisting of: hydrogen, hydroxy, halo, nitro, oxo, C₀₋₆alkylcyano, C₀₋₄alkylC₃₋₆cycloalkyl, C₁₋₆alkyl, -OC₁₋₆alkyl, C₁₋₆alkylhalo, OC₁₋₆alkylhalo, C₂₋₆alkenyl, C₀₋₃alkylaryl, C₀₋₆alkylOR⁵, OC₂₋₆alkylOR⁵, C₀₋₆alkylSR⁵, OC₂₋₆alkylSR⁵, (CO)R⁵, O(CO)R⁵, OC₂₋₆alkylcyano, OC₁₋₆alkylCO₂R⁵, O(CO)OR⁵, OC₁₋₆alkyl(CO)R⁵, C₁₋₆alkyl(CO)R⁵, NR⁵OR⁶, C₀₋₆NR⁵R⁶, OC₂₋₆alkylNR⁵R⁶, C₀₋₆alkyl(CO)NR⁵R⁶, OC₁₋₆alkyl(CO)NR⁵R⁶, OC₂₋₆alkylNR⁵(CO)R⁶, C₀₋₆alkylNR⁵(CO)R⁶, C₀₋₆alkylNR⁵(CO)NR⁵R⁶, O(CO)NR⁵R⁶, C₀₋₆alkyl(SO₂)NR⁵R⁶, OC₂₋₆alkyl(SO₂)NR⁵R⁶, C₀₋₆alkylNR⁵(SO₂)R⁶, OC₂₋₆alkylNR⁵(SO₂)R⁶, SO₃R⁵, C₁₋₆alkylNR⁵(SO₂)NR⁵R⁶, OC₂₋₆alkyl(SO₂)R⁵, C₀₋₆alkyl(SO₂)R⁵, C₀₋₆alkyl(SO)R⁵, OC₂₋₆alkyl(SO)R⁵ and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R⁵ and R⁶ are independently selected from, H, C₁₋₆alkyl, C₃₋₇cycloalkyl and aryl;

m is selected from 0, 1, 2, 3 or 4;

n is selected from 0, 1, 2, 3 or 4;

p is selected from 0, 1, 2, 3 or 4; and

a salt or hydrate thereof.

Another embodiment the invention relates to the compounds:

4-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidin-1-yl}-4-methyl-4H [1,2,4]triazol-3-yl)-pyridine

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine-1-carboxylic acid tert-butyl ester

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-1-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine-1-carboxylic acid tert-butyl ester

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-4-methyl-piperazine

2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine

4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-[5-(4-methoxyphenyl)-4-methyl-4H-1,2,4-triazol-3-yl]piperidine

[4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)phenyl]dimethylamine

[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-benzyl]-dimethyl-amine

{2-[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-phenoxy]-ethyl}-dimethyl-amine

(R)-3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine

(S) 3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine

(R)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine

(S)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine

(R)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

(S)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

This invention relates to polycyclic compounds of formula 1 having a variable P. In embodiments of the invention P is aryl. In particular embodiments of the invention P is phenyl.

In embodiments of the invention m is 1 or 2.

In particular embodiments of the invention P is phenyl having one or two substituents R^1 . In more particular embodiments of the invention, when there is one substituent R^1 the substituent is located at the 3-position of the phenyl relative to X^2 . In other particular embodiments of the invention when there are two substituents R^1 , the substituents are located at the 2- and 5-positions of the phenyl, relative to X^2 .

In another embodiment of the invention R^1 is selected from the group consisting of: hydrogen, halo, C_{1-6} alkylhalo, OC_{1-6} alkylhalo, C_{1-6} alkyl, OC_{1-6} alkyl, C_{1-6} alkylOR⁵, C_{0-6} alkylcyano, C_{0-6} alkylNR⁵R⁶. In still another embodiment of the invention R^1 is selected from the group consisting Cl, F, Me, OMe, CF₃, OCF₃, and CN. In yet another embodiment of the invention R^1 is Cl.

In embodiments of the invention X^7 is C. In other embodiments of the invention X^2 is C. In preferred embodiments of the invention at least one of X^2 and X^7 is C.

In another embodiment of the invention X3 is selected from N and O.

The invention further relates to compounds of Formula I wherein X^2 is C. Embodiments of the invention include those where X^1 is N or CR^4 . In a further embodiment of the invention when X^3 is O, X^4 is N and when X^3 is N, X^4 is O.

In another embodiment of the invention X^2 is N. In a further embodiment of the invention X^1 is N. In still a further embodiment of the invention X^3 is N and X^4 are N or CR^4 .

In another embodiment of the invention X^5 is selected from the group consisting of $CR^4R^{4'}$, NR^4 , O, S, SO and SO_2 . In a further embodiment of the invention X^5 is selected from the group consisting of $CR^4R^{4'}$, NR^4 and O. In yet a further embodiment of the invention X^5 is selected from the group consisting of O and NR^4 .

Particular embodiments of the invention include those where the ring containing X^1 , X^2 , X^3 and X^4 are selected such that the ring formed is a tetrazole, triazole, oxadiazole, oxazole, isoxazole, or imidazole ring. Preferably the ring is tetrazole, oxadiazole or isoxazole.


In embodiments of the invention X^6 is N. In further embodiments of the invention X^5 is selected from O and NR^4 . In still further embodiments of the invention X^5 is selected from $CR^4R^{4'}$.

In particular embodiments of the invention when the ring containing X^1 , X^2 , X^3 and X^4 is tetrazole, X^6 is N and X^5 is $CR^4R^{4'}$. In another particular embodiment of the invention when the ring containing X^1 , X^2 , X^3 and X^4 is selected from, oxadiazole and isoxazole, X^6 is N and X^5 is selected from O and NR^4 .


In another embodiment of the invention R^4 and $R^{4'}$ are independently selected from the group consisting of: hydrogen, C_{1-6} alkyl, C_{1-6} alkylhalo and halo.

The present invention relates to compounds of formula 1 have a ring Q. Embodiments of the invention include those where Q is heteroaryl. In preferred embodiments Q is selected

from the group consisting of:



In a more preferred embodiment of the invention the ring Q is



Embodiments of the invention include those where R^1 and R^2 are selected from the group consisting of: hydrogen, C_{1-4} alkylhalo, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{0-6} alkylaryl and C_{0-6} alkylheteroaryl.

In still another embodiment of the invention the variable any C_{1-6} alkyl, aryl, or heteroaryl defined under R^1 , R^2 and R^3 may be substituted by one or more substituents A. Particular embodiments of the invention include those where A is selected from the group consisting of: hydrogen, hydroxyl, halo, C_{0-6} alkylcyano, C_{1-6} alkyl, $-OC_{1-6}$ alkyl, C_{1-6} alkylhalo, OC_{1-6} alkylhalo.

Embodiments of the invention include salt forms of the compounds of Formula I. Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of Formula I.

A suitable pharmaceutically acceptable salt of the compounds of the invention is, for example, an acid-addition salt, for example an inorganic or organic acid. In addition, a suitable pharmaceutically acceptable salt of the compounds of the invention is an alkali metal salt, an alkaline earth metal salt or a salt with an organic base.

Other pharmaceutically acceptable salts and methods of preparing these salts may be found in, for example, Remington's Pharmaceutical Sciences (18th Edition, Mack Publishing Co.) 1990.

Some compounds of formula I may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomeric and geometric isomers.

The invention also relates to any and all tautomeric forms of the compounds of Formula I.

The invention further relates to hydrate and solvate forms of the compounds of Formula I.

Pharmaceutical composition

According to one aspect of the present invention there is provided a pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound of Formula I, or salts, solvates or solvated salts thereof, in association with one or more pharmaceutically acceptable diluent, excipients and/or inert carrier.

The composition may be in a form suitable for oral administration, for example as a tablet, pill, syrup, powder, granule or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration e.g. as an ointment, patch or cream or for rectal administration e.g. as a suppository.

In general the above compositions may be prepared in a conventional manner using one or more conventional excipients, pharmaceutical acceptable diluents and/or inert carriers.

Suitable daily doses of the compounds of formula I in the treatment of a mammal, including man are approximately 0.01 to 250 mg/kg bodyweight at peroral administration and about 0.001 to 250 mg/kg bodyweight at parenteral administration.

The typical daily dose of the active ingredients varies within a wide range and will depend on various factors such as the relevant indication, severity of the illness being treated, the route of administration, the age, weight and sex of the patient and the particular compound

being used, and may be determined by a physician.

Medical use

It has been found that the compounds according to the present invention, exhibit a high degree of potency and selectivity for individual metabotropic glutamate receptor (mGluR) subtypes. Accordingly, the compounds of the present invention are expected to be useful in the treatment of conditions associated with excitatory activation of mGluR 5 and for inhibiting neuronal damage caused by excitatory activation of mGluR 5. The compounds may be used to produce an inhibitory effect of mGluR 5 in mammals, including man.

The mGluR Group I receptor including mGluR 5 are highly expressed in the central and peripheral nervous system and in other tissues. Thus, it is expected that the compounds of the invention are well suited for the treatment of mGluR 5-mediated disorders such as acute and chronic neurological and psychiatric disorders, gastrointestinal disorders, and chronic and acute pain disorders.

The invention relates to compounds of Formula I, as defined hereinbefore, for use in therapy.

The invention relates to compounds of Formula I, as defined hereinbefore, for use in treatment of mGluR 5-mediated disorders.

The invention relates to compounds of Formula I, as defined hereinbefore, for use in treatment of Alzheimer's disease senile dementia, AIDS-induced dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, ophthalmological disorders such as retinopathies, diabetic retinopathies, glaucoma, auditory neuropathic disorders such as tinnitus, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, Fragile X, autism, mental retardation, schizophrenia and Down's Syndrome.

The invention relates to compounds of Formula I, as defined hereinbefore, for use in treatment of pain related to migraine, inflammatory pain, neuropathic pain disorders such as diabetic neuropathies, arthritis and rheumatoid diseases, low back pain, post-operative pain and pain associated with various conditions including angina, renal or biliary colic, menstruation, migraine and gout.

The invention relates to compounds of Formula I as defined hereinbefore, for use in treatment of stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.

The present invention relates also to the use of a compound of Formula I as defined hereinbefore, in the manufacture of a medicament for the treatment of mGluR Group I receptor-mediated disorders and any disorder listed above.

One embodiment of the invention relates to the use of a compound according to Formula I in the treatment of gastrointestinal disorders.

Another embodiment of the invention relates to the use of a compound according to Formula I, for the manufacture of a medicament for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of GERD, for the prevention of G.I. reflux, for the treatment regurgitation, treatment of asthma, treatment of laryngitis, treatment of lung disease and for the management of failure to thrive.

The invention also provides a method of treatment of mGluR 5-mediated disorders and any disorder listed above, in a patient suffering from, or at risk of, said condition, which comprises administering to the patient an effective amount of a compound of Formula I, as hereinbefore defined.

The dose required for the therapeutic or preventive treatment of a particular disorder will necessarily be varied depending on the host treated, the route of administration

and the severity of the illness being treated.

In the context of the present specification, the term "therapy" and "treatment" includes prevention or prophylaxis, unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.

In this specification, unless stated otherwise, the term "antagonist" and "inhibitor" shall mean a compound that by any means, partly or completely, blocks the transduction pathway leading to the production of a response by the ligand.

The term "disorder", unless stated otherwise, means any condition and disease associated with metabotropic glutamate receptor activity.

Non- Medical use

In addition to their use in therapeutic medicine, the compounds of Formula I, salts or hydrates thereof, are also useful as pharmacological tools in the development and standardisation of *in vitro* and *in vivo* test systems for the evaluation of the effects of inhibitors of mGluR related activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutics agents.

Methods of Preparation

Another aspect of the present invention provides processes for preparing compounds of Formula I, or salts or hydrates thereof. Processes for the preparation of the compounds in the present invention are described herein.

Throughout the following description of such processes it is to be understood that, where appropriate, suitable protecting groups will be added to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis. Conventional procedures for using such protecting groups as well as examples of suitable protecting groups are described, for

example, in "Protective Groups in Organic Synthesis", T.W. Green, P.G.M. Wuts, Wiley-Interscience, New York, (1999). It is also to be understood that a transformation of a group or substituent into another group or substituent by chemical manipulation can be conducted on any intermediate or final product on the synthetic path toward the final product, in which the possible type of transformation is limited only by inherent incompatibility of other functionalities carried by the molecule at that stage to the conditions or reagents employed in the transformation. Such inherent incompatibilities, and ways to circumvent them by carrying out appropriate transformations and synthetic steps in a suitable order, will be readily understood to the one skilled in the art of organic synthesis. Examples of transformations are given below, and it is to be understood that the described transformations are not limited only to the generic groups or substituents for which the transformations are exemplified. References and descriptions on other suitable transformations are given in "Comprehensive Organic Transformations – A Guide to Functional Group Preparations" R. C. Larock, VHC Publishers, Inc. (1989). References and descriptions of other suitable reactions are described in textbooks of organic chemistry, for example, "Advanced Organic Chemistry", March, 4th ed. McGraw Hill (1992) or, "Organic Synthesis", Smith, McGraw Hill, (1994). Techniques for purification of intermediates and final products include for example, straight and reversed phase chromatography on column or rotating plate, recrystallisation, distillation and liquid-liquid or solid-liquid extraction, which will be readily understood by the one skilled in the art. The definitions of substituents and groups are as in formula I except where defined differently. The term "room temperature" and "ambient temperature" shall mean, unless otherwise specified, a temperature between 16 and 25 °C. The term "reflux" shall mean, unless otherwise stated, in reference to an employed solvent a temperature at or above the boiling point of named solvent.

Abbreviations

aq. Aqueous

atm atmosphere

BINAP 2,2'Bis(diphenylphosphino)-1,1'-binaphthyl


Boc, BOC *tert*-butoxycarbonyl
CDIN, N'-Carbonyldiimidazole
dba Dibenzylideneacetone
DCC N,N-Dicyclohexylcarbodiimide
DCM Dichloromethane
DEA N,N-Diisopropylethylamine
DIBAL-H Diisobutylaluminum hydride
DICN, N'-Diisopropylcarbodiimide
DMAP N,N-Dimethyl-4-aminopyridine
DMF Dimethylformamide
DMSO Dimethylsulfoxide
DPPF 1,1'-Bis(diphenylphosphino)ferrocene
EA or EtOAc Ethyl acetate
EDC, EDCI N-[3-(dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride
Et Ethyl
Et₂O Diethyl ether
EtI Iodoethane
EtOH Ethanol
Et₃N Triethylamine
Fmoc, Fmoc 9-Fluorenylmethoxycarbonyl
h hour(s)
HBTU O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
HetAr Heteroaryl
HOBt N-Hydroxybenzotriazole
HPLC high performance liquid chromatography
LCMS HPLC mass spec
MCPBA *m*-chlorbenzoic acid
Me Methyl
MeCN Acetonitrile
MeI Iodomethane
MeMgCl methyl magnesium chloride

MeOH	Methanol
min	Minutes
NaOAc	sodium acetate
<i>n</i> Bu	normal butyl
<i>n</i> BuLi, <i>n</i> -BuLi	1-butyllithium
NCS	N-chlorosuccinimide
NMR	nuclear magnetic resonance
o.n.	over night
OAc	acetate
OMs	mesylate or methane sulfonate ester
OTs	tosylate, toluene sulfonate or 4-methylbenzene sulfonate ester
PPTS	pyridinium <i>p</i> -toluenesulfonate
<i>p</i> TsOH	<i>p</i> -toluenesulfonic acid
RT, rt, r.t.	room temperature
sat.	Saturated
SPE	solid phase extraction (usually containing silica gel)
TBAF	tetrabutylammonium fluoride
<i>t</i> Bu, <i>t</i> -Bu	<i>tert</i> -butyl
<i>t</i> BuOH, <i>t</i> -BuOH	<i>tert</i> -butanol
TEA	Triethylamine
THF	Tetrahydrofuran

Preparation of intermediates

The intermediates provided in synthetic paths given below, are useful for further preparation of compounds of formula I. Other starting materials are either commercially available or can be prepared via methods described in the literature. The synthetic pathways described below are non-limiting examples of preparations that can be used. One of skill in the art would understand other pathways might be used.


Synthesis of Isoxazoles



Scheme 1

Aldehydes of formula **vi** wherein X^5 is as defined in formula I may be used in the preparation of isoxazoles. Commercially available acid derivatives of formula **ii** wherein X^5 is O, S, C, N- R^2 and N- G^2 (G^2 is a protecting group orthogonal to G^1) may undergo N-protection to yield compounds of formula **iii** wherein G^1 is a protecting group such as Boc or Fmoc using methods well known in the art. The acid moiety in compounds of formula **iii** may be transformed into an alkyl ester of formula **iv**, such as for example the methyl or ethyl ester, which may be transformed to aldehydes of formula **vi** using a mild reducing agent such as DIBAL-H in a solvent such as toluene at low temperature, for example -78°C . Higher temperatures or stronger reducing agents may result in formation of the primary alcohols of formula **v**, either exclusively or as a mixture with the aldehydes of formula **vi**. Other functional groups such as the primary alcohol in compounds of formula **v**, the nitrile in compounds of formula **vii** and Weinreb amide moiety in compounds of formula **viii** may be transformed into aldehydes of formula **vi** utilizing procedures established in the art. Additionally, acids of formula **ii** may be converted into nitriles of formula **vii** by methods known in the art, for example by conversion of the acid to the primary amide followed by dehydration to the nitrile.


Aldehydes of formula vi may be converted to oximes of formula ix by treatment with hydroxylamine, in a solvent such as pyridine, at a temperature between 0 °C to room temperature. Isoxazoles of formula x may be prepared by chlorination of oximes of formula ix using a reagent such as N-chlorosuccinimide (NCS), followed by 1,3-dipolar cycloaddition with the appropriately R-substituted acetylenes, wherein R may be $(R^1)_m$ -P or a masking group which may later be converted to $(R^1)_m$ -P (Steven, R. V. et al. *J. Am. Chem. Soc.* 1986, 108, 1039). The isoxazole intermediate x can subsequently be deprotected to give xi by standard methods.



Scheme 2

Isoxazoles of formula x wherein R is a masking group may be prepared in this manner and the masking group transformed into $(R^1)_m$ -P subsequent to isoxazole ring formation. For example, the use of trialkylstannylacetylenes would result in a trialkylstannyl isoxazole which may undergo reactions such as for example Stille type cross coupling to introduce aryl substituents by coupling to an appropriate aryl halide.


Synthesis of [1,2,4]-Oxadiazoles



Scheme 3

Carboxylic acids of formula iii may be used in the preparation of the corresponding 3-R substituted [1,2,4]oxadiazoles of formula xii by activation of the acid moiety, addition of a suitable R-substituted hydroxyamidinium to form an ester, followed by cyclization to the


oxadiazole. [See Tetrahedron Lett., 2001, 42, 1495-98, Tetrahedron Lett., 2001, 42, 1441-43, and Bioorg. Med. Chem. Lett. 1999, 9, 1869-74]. The acid may be activated as the mixed anhydride using an alkyl chloroformate such as isobutyl chloroformate, in the presence of a base such as triethylamine in a suitable solvent such as THF. Alternatively, other well known methods of activating the acid may be employed, including *in situ* activation of the acid using a reagent such as EDCI, DCC, DIC or HBTU, with or without the presence of co-reagents such as HOBT or DMAP, in suitable solvents such as DMF, DCM, THF, or MeCN at a temperature from -20 to 100 °C. The cyclization may be accomplished by heating in a solvent such as pyridine or DMF, under microwave irradiation or by employing catalysts such as TBAF. R-substituted hydroxyamidines are available from nitriles by addition of hydroxylamine hydrochloride in the presence of a base such as NaOH, NaHCO_3 or Na_2CO_3 , to generate the free hydroxylamine, in a solvent such as ethanol or methanol or the like, at temperatures between room temperature and 100 °C.



Scheme 4

Compounds of formula ii wherein X is N-G^2 provides a convenient method of obtaining the free NH compound of formula I. For example, the commercially available acid derivative of formula iia wherein X is N-Boc may be orthogonally N-protected with a protecting group G^1 such as for example Fmoc. The resulting intermediate iiia may be transformed into the corresponding [1,2,4]-oxadiazoles using methods described above. When Fmoc is employed for one of the protecting groups, [1,2,4]-oxadiazole ring formation methods involving a base, such as activation with chloroformate in the presence of triethylamine or ring closure in pyridine, may effect removal of the protecting group giving xiiia directly without isolation of the 2-(3-R-[1,2,4]oxadiazol-5-yl)-piperazine


intermediate.



Scheme 5

5-R substituted [1,2,4]oxadiazoles of formula xiib may be prepared from nitriles of formula vii by effectively reversing the substituents attached to the [1,2,4]-oxadiazole. Nitriles of formula vii react with hydroxylamine as described above to provide the intermediate hydroxyamidine, and may be converted to the [1,2,4]oxadiazoles of formula xiib using an acylating agent containing the R group using the method described above for conversion of compounds of formula iii to compounds of formula xii.

Synthesis of Tetrazoles




Scheme 6

Nitriles of formula vii may be used in the preparation of the corresponding tetrazoles of formula xviii by treatment with an azide, such as NaN_3 , LiN_3 , trialkyltin azide or trimethylsilylazide, preferably with a catalyst such as dibutyltin oxide or ZnBr_2 , in solvents such as DMF, water or toluene at a temperature of 80 to 200 °C by conventional heating or microwave irradiation [See J. Org. Chem. 2001, 7945-7950; J. Org. Chem. 2000, 7984-7989 or J. Org. Chem. 1993, 4139-4141].

N2-arylation of 5-substituted tetrazoles have been reported in the literature using a variety

of coupling partners. Compounds of formula xviii wherein R is an aryl group may be prepared using for example boronic acids of formula xv [with the B(OH)₂ moiety], or the corresponding iodonium salts of formula xvii [with the I⁺-Ar moiety], or the corresponding triarylbismuth diacetates [with the Bi(OAc)₂Ar₂ moiety], as arylating agents mediated by transition metals [See Tetrahedron Lett. 2002, 6221-6223; Tetrahedron Lett. 1998, 2941-2944; Tetrahedron Lett. 1999, 2747-2748]. With boronic acids, stoichiometric amounts of Cu(II)acetate and pyridine are used in solvents such as dichloromethane, DMF, dioxane or THF at a temperature of room temperature to 100 °C. With iodonium salts, catalytic amounts of Pd(II)-compounds, such as Pd(dba)₂ or Pd(OAc)₂, together with catalytic amounts of Cu(II)-carboxylates, such as Cu(II)-phenylcyclopropylcarboxylate, and bidentate ligands, such as BINAP or DPPF, are used in solvents such as *t*-BuOH at a temperature of 50 to 100 °C. With triarylbismuth diacetates, catalytic amounts of cupric acetate may be employed in the presence of N,N,N',N'-tetramethylguanidine in a suitable solvent such as THF with heating at a temperature of 40-60°C. Iodonium salts of formula xvi may be obtained from, for example, the respective boronic acids by treatment with hypervalent iodine substituted aromatics, such as hydroxyl(tosyloxy)iodobenzene or PhI(OAc)₂·2TfOH, in dichloromethane or the like [See Tetrahedron Lett. 2000, 5393-5396]. Triarylbismuth diacetates may be prepared from aryl magnesium bromides with bismuth trichloride in a suitable solvent such as refluxing THF to give the triarylbismuthane, which is then oxidized to the diacetate using an oxidizing agent such as sodium perborate in acetic acid [Synth. Commun. 1996, 4569-75].


Synthesis of [1,2,3]triazoles



Scheme 7

Ketoaldehydes of formula xix are available from compounds of formula ii via activation of the acid moiety, reaction with diazomethane to form an intermediate alpha-diazoketone, and trapping with an acid such as acetic acid to form an alpha-acetylated ketone intermediate, which can be converted to compounds of formula xix by hydrolysis and oxidation. [See Bioorg. Med. Chem. 2002, 10, 2199-2206] Ketoaldehydes of formula xix will react with arylhydrazines with in acetic acid and water at -20 to 120 °C to form bis-hydrazones of formula xx, which may undergo cyclization in the presence of copper (II) sulfate in aqueous mixtures of for example dioxane or THF at -20 to 120 °C to form [1,2,3]triazoles of formula xxi. [See J. Med. Chem. 1978, 21, 1254-60 and J. Org Chem. 1948, 13, 807-14] Compounds of formula xxi may be deprotected as above to yield the secondary amines of formula xxii.

Synthesis of Q Ring: Amino-Triazoles




Scheme 8

The deprotected amines of formula xi, xiii, xviii and xxii may be subjected to a sequence of thiourea formation, methylation and triazole formation to deliver compounds of formula I wherein the Q ring is a triazole attached to the newly deprotected secondary amine.

Thioureas of formula xxiv are available from well established methods using for example an isothiocyanate, R^2SCN , or 1,1-thiocarbonyl-diimidazole in the presence of R^2NH_2 , in a solvent such as methanol, ethanol and the like, at a temperature between room temperature and 100 °C, and are typically carried out at 60 °C. Alkylation of the thiourea intermediates can be performed using an alkylating agents such iodomethane or iodoethane, in a solvent such as DMF, acetone, CH_2Cl_2 , at room temperature or elevated temperatures to give the

isothiourea of formula xxv. When an iodoalkane is employed, the product may be isolated as the hydroiodide salt [See Synth.Comm. 1998, 28, 741-746]. Compounds of formula xxv may react with an acyl hydrazine or with hydrazine followed by an acylating agent to form an intermediate which may be cyclized to the 3-aminotriazoles of formula xxvi by heating at 50 to 200 °C in a suitable solvent such as pyridine or DMF.

Other Functional Group transformations



Scheme 9

It is to be understood that when additional functional groups are present in compounds of formula I or any precursor, those functional groups may be employed to introduce other substituents or functional groups by methods established in the art when there are no other incompatible reactive sites. For example, in compounds of formula xxvii available from the orthogonally protected bisamine xiiia described above, the secondary amine obtained by deprotection of G² may undergo alkylation or reductive amination to generate a tertiary amine of formula xix. Additionally, other substituents not explicitly drawn in the schemes may be present as described in formula I providing no interference with the reactions described above is caused by said substituents.

The invention further relates to the following compounds, which may be used as intermediates in the preparation of compounds of formula I;

Methyl 4-dimethylaminomethyl-benzoate

Ethyl 4-(2-dimethylamino-ethoxy)-benzoate

4-Dimethylaminomethyl-benzoic acid hydrazide
4-(2-Dimethylamino-ethoxy)-benzoic acid hydrazide
4-Difluoromethoxy-benzoic acid hydrazide
Tris-(3-chloro-phenyl)-bismuthane
Tris-(3-chloro-phenyl)-bismuthane diacetate
2-Hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester
Morpholine-3,4-dicarboxylic acid 4-tert-butyl ester
Piperazine-1,2,4-tricarboxylic acid 4-tert-butyl ester 1-(9H-fluoren-9-ylmethyl) ester
2-Formyl-piperidine-1-carboxylic acid tert-butyl ester
Morpholine-3,4-dicarboxylic acid 4-tert-butyl ester 3-methyl ester
3-Formyl-morpholine-4-carboxylic acid tert-butyl ester
2-Cyano-piperidine-1-carboxylic acid tert-butyl ester
2-(1H-Tetrazol-5-yl)-piperidine-1-carboxylic acid tert-butyl ester
2-(Hydroxyimino-methyl)-piperidine-1-carboxylic acid tert-butyl ester
3-(Hydroxyimino-methyl)-morpholine-4-carboxylic acid tert-butyl ester
2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidine-1-carboxylic acid tert-butyl ester
3-[5-(3-chloro-phenyl)-isoxazol-3-yl]-morpholine-4-carboxylic acid tert-butyl ester
3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholine-4-carboxylic acid tert-butyl ester
3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazine-1-carboxylic acid tert-butyl ester
2-[2-(3-chloro-phenyl)-2H-tetrazol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester
2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidine
3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-morpholine
3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholine
2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidine
2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidine-1-carbothioic acid methylamide
3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-morpholine-4-carbothioic acid methylamide
3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholine-4-carbothioic acid methylamide
3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methylthiocarbamoyl-piperazine-1-

carboxylic acid tert-butyl ester

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidine-1-carbothioic acid methylamide

2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-N-methyl-morpholine-4-carboximidothioic acid methyl ester

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-methylmorpholine-4-carboximidothioic acid methyl ester

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(methylimino-methylsulfanyl-methyl)-piperazine-1-carboxylic acid tert-butyl ester

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester

Examples

The invention will now be illustrated by the following non-limiting examples.

General methods

All starting materials are commercially available or earlier described in the literature.

The ^1H and ^{13}C NMR spectra were recorded either on Bruker 300, Bruker DPX400 or Varian +400 spectrometers operating at 300, 400 and 400 MHz for ^1H NMR respectively, using TMS or the residual solvent signal as reference, in deuterated chloroform as solvent unless otherwise indicated. All reported chemical shifts are in ppm on the delta-scale, and the fine splitting of the signals as appearing in the recordings (s: singlet, br s: broad singlet, d: doublet, t: triplet, q: quartet, m: multiplet).

Analytical in line liquid chromatography separations followed by mass spectra detections, were recorded on a Waters LCMS consisting of an Alliance 2795 (LC) and a ZQ single quadrupole mass spectrometer. The mass spectrometer was equipped with an electrospray ion source operated in a positive and/or negative ion mode. The ion spray voltage was ± 3 kV and the mass spectrometer was scanned from m/z 100-700 at a scan time of 0.8 s. To the column, X-Terra MS, Waters, C8, 2.1 x 50mm, 3.5 mm, was applied a linear

gradient from 5 % to 100% acetonitrile in 10 mM ammonium acetate (aq.), or in 0.1% TFA (aq.).

Preparative reversed phase chromatography was run on a Gilson autopreparative HPLC with a diode array detector using an XTerra MS C8, 19x300mm, 7mm as column.

Purification by a chromatotron was performed on rotating silica gel / gypsum (Merck, 60 PF-254 with calcium sulphate) coated glass sheets, with coating layer of 1, 2, or 4 mm using a TC Research 7924T chromatotron. Purification of products were also done by flash chromatography in silica-filled glass columns or in plastic SPE tubes pre-filled with silica gel.

Microwave heating was performed in a Smith Synthesizer Single-mode microwave cavity producing continuous irradiation at 2450 MHz (Personal Chemistry AB, Uppsala, Sweden).

Example 1

Methyl 4-dimethylaminomethyl-benzoate

Methyl 4-(bromomethyl)benzoate (4.58 g, 20 mmol) was mixed with 45% dimethylamine (5.57 mL, 2.5 mmol) in THF (50 mL) at room temperature for 30 min. The mixture was concentrated *in vacuo* and the residue was diluted with water and extracted with ether. The organic layer was dried with MgSO_4 and concentrated *in vacuo* to give the title compound (4.0g) as pale yellow oil. ^1H NMR (CDCl_3), δ (ppm): 8.01 (d, 2H), 7.40 (d, 2H), 3.92 (s, 3H), 3.48 (s, 2H) and 2.26 (s, 6H).

Example 2

Ethyl 4-(2-dimethylamino-ethoxy)-benzoate

Ethyl 4-hydroxy-benzoate (16.6 g, 0.1 mol) was mixed with (2-chloro-ethyl)-dimethylamine hydrochloride (40 g, 0.28 mol) and K_2CO_3 (100 g, 0.724 mol) in DMF. The mixture was heated to 150 °C for 4 h, and then poured into ice-water and the product was extracted into ethyl acetate. The ethyl acetate layer was washed with brine and the product was acidified with 1N HCl (130 mL) and the ethyl acetate layer was discarded. The acidified

aqueous layer was washed with ethyl acetate, then basified with 2M sodium carbonate (100 mL) and the product was extracted into ethyl acetate again. This organic layer was washed with brine, dried with MgSO_4 , filtered and concentrated to give the title compound (12.6 g, 53%) as a sticky pale yellow-brown oil. ^1H NMR (CDCl_3), δ (ppm): 8.01 (d, 2H), 6.95 (d, 2H), 4.36 (q, 2H), 4.13 (t, 2H), 2.76 (t, 2H), 2.36 (s, 6H) and 1.39 (t, 3H).

Example 3

4-Dimethylaminomethyl-benzoic acid hydrazide

Methyl 4-dimethylaminomethyl-benzoate (4.0 g, 20 mmol) was mixed with hydrazine hydrate (9.7 ml, 200 mmol) in methanol at 80 °C overnight. The mixture was concentrated *in vacuo* and the residue was triturated with ether to give the title compound (3.37g, 84.2%) as a white solid. ^1H NMR (DMSO-d_6), δ (ppm): 9.75 (w, 1H), 7.76 (d, 2H), 7.35 (d, 2H), 4.50 (w, 2H), 3.41 (s, 2H) and 2.13 (s, 6H).

Example 4

4-(2-Dimethylamino-ethoxy)-benzoic acid hydrazide

Ethyl 4-(2-dimethylamino-ethoxy)-benzoate (12.6 g, 53 mmol) was mixed with hydrazine hydride (26.5 g, 0.5 mol) in ethanol at 100 °C in a sealed flask overnight. The mixture was concentrated and triturated with ether to give the title compound (9.83g, 82.9%) as a pale yellow solid. ^1H NMR (DMSO-d_6), δ (ppm): 9.62 (s, 1H), 7.77 (d, 2H), 6.97 (d, 2H), 4.45 (b, 2H), 4.08 (t, 2H), 2.61 (t, 2H) and 2.20 (s, 6H).

Example 5

4-Difluoromethoxy-benzoic acid hydrazide

HOBt (2.2 g, 15.9 mmol) and EDCI (3.1 g, 15.9 mmol) were added to 4-difluoromethoxy-benzoic acid (2.5 g, 13.3 mmol) in acetonitrile (25 mL) at room temperature. After two hours, a solution of hydrazine monohydrate (0.493 mL, 10.2 mmol) and cyclohexane (0.33 mL) in acetonitrile (5.0 mL) was added drop-wise at 0°C. After stirring at room temperature for 2 hours, the solvent was removed *in vacuo* and the residue was diluted

with ethyl acetate, washed saturated sodium bicarbonate (4 times), dried over sodium sulfate, filtered and concentrated to afford the title compound (2.12 g, 79%, white solid). ^1H NMR (DMSO) δ (ppm): 9.80 (bs, 1H), 7.88 (m, 2H), 7.34 (t, 1H), 7.23 (m, 2H), 4.50 (bs, 2H).

Example 6

Tris-(3-chloro-phenyl)-bismuthane

Bismuth trichloride (1 mmol) is slowly added to 3-chlorophenyl magnesium bromide (3.3 mmol) in THF (6.6 mL) at 0 °C. The reaction is refluxed for 30 min, and stirred at room temperature overnight prior to quenching by addition of ammonium chloride and extraction into dichloromethane. The organic layer is dried (magnesium sulfate), filtered and concentrated *in vacuo*. Recrystallization or chromatography on silica gel yields the title compound.

Example 7

Tris-(3-chloro-phenyl)-bismuthane diacetate

A mixture of sodium perborate monohydrate (3 mmol), tris-(3-chloro-phenyl)-bismuthane (1 mmol) in acetic acid (10 mL) is stirred at room temperature for 1 h. The mixture is quenched by pouring into water and the product is extracted into dichloromethane. The organic layer is washed with water, dried over magnesium sulfate, filtered and concentrated *in vacuo*. Crystallization from a mixture of ether in pentane mixture yields the title compound.

Example 8

2-Hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester

Di-*tert*-butyl dicarbonate (8.3 g, 38.2 mmol) was added to a stirred solution of piperidinemethanol (4.0g, 37.4 mmol) in CH_2Cl_2 (50 mL) and 1N NaOH (50 mL, 50 mmol) was added. The mixture was stirred at room temperature overnight. Reaction mixture was diluted with CH_2Cl_2 and the aqueous phase was separated. The aqueous

phase was extracted with dichloromethane (3X30 mL). The combined organic phase was washed with water (30 mL) and brine (30 mL), dried (sodium sulfate), filtered and concentrated *in-vacuo* to give the crude product which was triturated with hexane to afford the title compound as white solid (4.8 g, 64%).

Example 9

Morpholine-3,4-dicarboxylic acid 4-tert-butyl ester

Di-tert-butyl dicarbonate (3.33 g, 15.3 mmol) was added to a solution of morpholine-3-carboxylic acid (1.7 g, 10.2 mmol), potassium carbonate (7.04 g, 51 mmol) in acetone (5 mL) and water (10 mL) at 0°C. The resulting mixture was stirred at room temperature for 24 h, diluted with water (50 mL) and extracted with diethyl ether (2X50 mL). The aqueous phase was treated with hydrochloric acid (2M aqueous, 100 mL), extracted with dichloromethane (2X50 mL). The combined organic phase was washed with water (50 mL), brine (50 mL), dried (sodium sulfate), filtered and concentrated *in-vacuo* to isolate the desired product as white solid (1.98 g, 84%). ¹H NMR (CDCl₃), δ (ppm): 4.46 (m, 2H), 3.80 (m, 3H), 3.53 (m, 1H), 3.31 (m, 1H), 1.48 (d, 9H).

Example 10

Piperazine-1,2,4-tricarboxylic acid 4-tert-butyl ester 1-(9H-fluoren-9-ylmethyl) ester

A solution of 9-fluorenylmethyl chloroformate (2.72 g, 10.5 mmol) in 1,4-dioxane (19 mL) was added drop-wise to a solution of piperazine-1,3-dicarboxylic acid 1-tert-butyl ester (2.20 g, 9.6 mmol) and *N,N*-diisopropylethylamine (4.2 mL, 23.9 mmol) in water (9.5 mL) in an ice-bath. After stirring overnight at room temperature, the reaction mixture was diluted with water and extracted with chloroform (4 times). The organic layer was washed with saturated sodium bicarbonate and water and then 1N HCl and water, dried over anhydrous sodium sulfate, filtered, and concentrated to afford piperazine-1,2,4-tricarboxylic acid 4-tert-butyl ester 1-(9H-fluoren-9-ylmethyl) ester (4.3g).

Example 11**2-Formyl-piperidine-1-carboxylic acid tert-butyl ester**

DMSO (7.14 mL, 98 mmol) was added drop-wise to a stirred solution of oxalyl chloride (30 mL, 2M in CH₂Cl₂, 60 mmol) in CH₂Cl₂ (60 mL) at -78°C. After 5 minutes, a solution of 2-hydroxymethyl-piperidine-1-carboxylic acid tert-butyl ester in CH₂Cl₂ (25 mL) was added and the reaction mixture was stirred at -78°C for 0.5 hours after which Et₃N (25 mL, 181 mmol) was added and the mixture allowed to warm slowly to room temperature with stirring. The mixture was then poured into water (100 mL) and the organic layer was separated. The organic extract was then washed with NaHCO₃ (saturated). The aqueous phase was extracted with dichloromethane (3X30 mL). The combined organic phase was washed with water (30 mL) and brine (30 mL), dried (sodium sulfate), filtered and concentrated *in vacuo*. Chromatography gave the title product as a yellow oil (3.27 g, 73%).

Example 12**Morpholine-3,4-dicarboxylic acid 4-tert-butyl ester 3-methyl ester**

Iodomethane (0.32 mL, 5.19 mmol) was added to a solution of morpholine-3,4-dicarboxylic acid 4-tert-butyl ester (1 g, 4.32 mmol) and potassium carbonate in DMF (15 mL). The resulting mixture was stirred at room temperature for 4 h, diluted with diethyl ether (100 mL), and successively washed with water (3X100 mL) and brine (100 mL). The organic phase was dried (sodium sulfate), filtered and concentrated *in-vacuo* to isolate the desired compound as clear oil (0.99 g, 94%). ¹H NMR (CDCl₃), δ (ppm): 4.40 (m, 2H), 3.75 (m, 6H), 3.39 (m, 2H), 1.46 (d, 9H).

Example 13**3-Formyl-morpholine-4-carboxylic acid tert-butyl ester**

Diisobutylaluminum hydride (1M in toluene), was added drop-wise to a solution of morpholine-3,4-dicarboxylic acid 4-tert-butyl ester 3-methyl ester (992 mg, 4.05 mmol) in toluene (10 mL) at -78°C, and left stirring at -78°C for 1h. The reaction was quenched by slow addition of sodium sulfate decahydrate (0.6 g) with stirring at 80°C for 40 minutes. The mixture was filtered while hot through a celite pad using ethyl acetate. The filtrate

was concentrated *in vacuo* and chromatography (silica gel, 8% acetone in hexanes) yielded the title product as a white solid (539 mg, 62%). ¹H NMR (CDCl₃), δ (ppm): 9.68 (s, 1H), 4.45 (m, 2H), 3.86 (m, 2H), 3.70 (dd, 1H), 3.51 (m, 1H), 3.23 (m, 1H), 1.48 (m, 9H).

Example 14

2-Cyano-piperidine-1-carboxylic acid tert-butyl ester

Piperidine-1,2-dicarboxylic acid-1-tert-butyl ester (12.8 g, 55.6 mmol) and THF (170 mL) were added to a 500 mL round bottom flask equipped with stir bar. The solution was cooled to –20°C and triethylamine (10.1 mL, 72.3 mmol) was added followed by ethyl chloroformate (5.32 mL, 55.6 mmol). The resulting white precipitate was left stirring at –10°C for 1 h. Aqueous ammonia (22.6 mL, 1168 mmol) was added to the above reaction mixture and the clear reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated *in vacuo* and the isolated residue was dissolved in ethyl acetate (300 mL). The organic phase was successively washed with water (300 mL) and brine (200 mL), dried (sodium sulfate), filtered and concentrated *in vacuo* to isolate a clear gum. The gum was triturated with hexanes to isolate the title compound (9.4 g, 74%) as a white solid. ¹H NMR (CDCl₃), δ (ppm): 6.03 (bs, 1H), 5.55 (bs, 1H), 4.77 (bs, 1H), 4.05 (bs, 1H), 2.81 (t, 1H), 2.27 (bs, 1H), 1.47 (m, 14H).

Acetonitrile (220 mL) and DMF (3.82 mL, 49.4 mmol) were added to a 500 mL round bottom flask equipped with stir bar. Cooled the mixture down to –5°C and to it added oxalyl chloride (24.7 mL, 49.4 mmol, 2 M dichloromethane). The resulting mixture was stirred for 15 min. This was followed by addition of solution of 2-carbamoyl-piperidine-1-carboxylic acid tert-butyl ester (9.4 g, 41.2 mmol) in acetonitrile (50 mL) and pyridine (8.3 mL, 103 mmol). Reaction mixture was left stirring at room temperature overnight. The reaction mixture was concentrated *in vacuo* and the residue was dissolved in ethyl acetate (300 mL). The organic phase was successively washed with water (300 mL) and brine (200 mL), dried (sodium sulfate), filtered and concentrated *in vacuo* to isolate the title compound (8.44 g, 97%) as a yellow solid. ¹H NMR (CDCl₃), δ (ppm): 5.23 (bs, 1H), 4.03 (bs, 1H), 2.93 (t, 1H), 1.75 (m, 5H), 1.46 (m, 10H).

Example 15**2-(1H-Tetrazol-5-yl)-piperidine-1-carboxylic acid tert-butyl ester**

A mixture of 2-cyano-piperidine-1-carboxylic acid tert-butyl ester (1 mmol), sodium azide (1 mmol) and ammonium chloride (1.1 mmol) in DMF (0.75 mL) is heated at 95 °C for 6 h. The reaction is quenched by pouring onto ice and acidification with dilute hydrochloric acid, and the product is extracted into chloroform. The organic layer is sequentially washed with water and brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. Chromatography on silica gel yields the title compound.

Example 16**2-(Hydroxyimino-methyl)-piperidine-1-carboxylic acid tert-butyl ester**

2-Formyl-piperidine-1-carboxylic acid tert-butyl ester (1.0 g, 4.7 mmol) in pyridine (1.3 mL) was added to a solution of hydroxylamine hydrochloride (407 mg, 5.9 mmol) in pyridine (5.0 mL) at 0°C, and the mixture was stirred at room temperature for 12 h. The mixture was diluted with water (50 mL), extracted with dichloromethane (3X25 mL). The combined organic phase was washed with brine (50 mL), dried (sodium sulfate), filtered and concentrated *in vacuo* to isolate the desired compound as light yellow oil (1.0g).

Example 17**3-(Hydroxyimino-methyl)-morpholine-4-carboxylic acid tert-butyl ester**

A solution of 3-formyl-morpholine-4-carboxylic acid tert-butyl ester (539 mg, 2.50 mmol) in pyridine (1.3 mL) was added to a solution of hydroxylamine hydrochloride (217 mg, 3.13 mmol) in pyridine (2.5 mL) at 0°C. The mixture was warmed to room temperature and stirred for 12 h, diluted with water (50 mL), and extracted with dichloromethane (3X25 mL). The combined organic phase was washed with brine (50 mL), dried (sodium sulfate), filtered and concentrated, *in-vacuo* to isolate the desired compound as light yellow oil (578 mg).

Example 18**2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidine-1-carboxylic acid tert-butyl ester**

N-chlorosuccinimide (643 mg, 4.82) in DMF (6 mL) was added to 2-(hydroxyimino-methyl)-piperidine-1-carboxylic acid tert-butyl ester (1.0 g, 4.38 mmol) in dimethylformamide (10 mL) at 40°C. The mixture was stirred at 40°C for 1.5 h, cooled to room temperature, diluted with diethyl ether (75 mL), and sequentially washed with water (3X100 mL) and brine (100 mL). The organic phase was dried (sodium sulfate), filtered and concentrated *in vacuo*, to give the intermediated as yellow oil.

The intermediate in dichloromethane (5 mL) was added to 3-chloro-1-ethynylbenzene (1.24 mL, 10 mmol) and triethylamine (1.05 mL, 7.54 mmol) and dichloromethane (5 mL) at 0°C and the mixture was stirred at room temperature for 12 h, and concentrated *in vacuo*. The residue was dissolved in ethyl acetate (75 mL), and sequentially washed with water (3X50 mL) and brine (50 mL). The organic phase was dried (sodium sulfate), filtered and concentrated *in vacuo*. Chromatography (silica gel, 2% ethyl acetate in dichloromethane) gave the title compound as a yellow solid (236 mg). ¹H NMR (CDCl₃), δ (ppm): 7.75 (dd, 1 H), 7.64 (m, 1 H), 7.40 (m, 2 H), 6.37 (s, 1H), 5.48 (br, 1H), 4.08 (m, 1H), 2.83 (m, 1H), 2.35 (m, 1H), 2.00-1.53 (m, 5H), 1.52 (s, 9H).

Example 19**3-[5-(3-chloro-phenyl)-isoxazol-3-yl]-morpholine-4-carboxylic acid tert-butyl ester**

A solution of N-chlorosuccinimide in dimethylformamide (6 mL) was added to a solution of 3-(hydroxyimino-methyl)-morpholine-4-carboxylic acid tert-butyl ester (578 mg, 2.51 mmol) in dimethylformamide (10 mL) at 40 °C, and the mixture was stirred at 40°C for 1.5 h. The reaction mixture was cooled to room temperature, diluted with diethyl ether (75 mL), sequentially washed with water (3X100 mL) and brine (100 mL). The organic phase was dried (sodium sulfate), filtered and concentrated, *in-vacuo*, to isolate the intermediate as clear oil.

The intermediate in dichloromethane (5 mL) was added to a solution of 3-chloro-1-ethynylbenzene (1.24 mL, 10 mmol), triethylamine (1.05 mL, 7.54 mmol) in

dichloromethane (5 mL) at 0 °C and the mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated *in vacuo*, dissolved in ethyl acetate (75 mL), and sequentially washed with water (3X50 mL) and brine (50 mL). The organic phase was dried (sodium sulfate), filtered and concentrated, *in-vacuo*. Chromatography (silica gel, 2% ethyl acetate in dichloromethane) yielded the title compound as a yellow solid (236 mg). ¹H NMR (CDCl₃), δ (ppm): 7.76 (bs, 1H), 7.67 (m, 1H), 7.43 (m, 2H), 6.51 (s, 1H), 5.24 (m, 1H), 4.39 (d, 1H), 3.88 (m, 3H), 3.60 (dt, 1H), 3.24 (m, 1H), 1.52 (s, 9H).

Example 20

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholine-4-carboxylic acid tert-butyl ester

Isobutyl chloroformate (0.42 mL, 3.24 mmol) was added to a solution of morpholine-3,4-dicarboxylic acid 4-tert-butyl ester (500 mg, 2.16 mmol) and triethylamine (0.805 mL, 5.79 mmol) in THF (15 mL) at 0°C. The mixture was warmed to room temperature for 2 hours. 3-Chloro-N-hydroxy-benzamidine was added (368 mg, 2.16 mmol) and the mixture was stirred overnight at room temperature, then cooled and diluted with ethyl acetate (350 mL). The organic layer was washed with water (2 x 30 mL) and brine (30 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. Chromatography (silica gel, 30-40% ethyl acetate in hexanes) yielded the ester (755 mg, 91%). ¹H NMR (CDCl₃), δ (ppm): 7.73 (s, 1H), 7.60 (d, 1H), 7.47 (d, 1H), 7.38 (dd, 1H), 5.25 (d, 2H), 4.4-4.8 (m, 2H), 4.1-3.2 (m, 5H), 1.50 (s, 9H).

A solution of the ester in DMF was heated at 127°C for 2 hours. The product was extracted into ethyl acetate (100 mL) and the organic layer was washed with water (3 x 20 mL) and brine (20 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The title compound (783 mg,) was obtained in quantitative yield. ¹H NMR (CDCl₃): 8.09 (s, 1H), 7.98 (d, 1H), 7.46 (m, 2H), 4.50 (s, 1H), 4.2-3.2 (m, 6H), 1.49 (s, 9H).

Example 21**3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazine-1-carboxylic acid tert-butyl ester**

Piperazine-1,2,4-tricarboxylic acid 4-tert-butyl ester 1-(9H-fluoren-9-ylmethyl) ester (4.3 g, 9.6 mmol), 3-chloro-N-hydroxy-benzamidine (1.8 g, 10.5 mmol), HOBt (1.4 g, 10.5 mmol) and EDCI (2.0 g, 10.5 mmol) in DMF (25 mL) were stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate, washed with water (3 times), saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was dissolved in DMF (20 mL) and then heated at 135°C for 2 hours. After cooling, the reaction mixture was diluted with ethyl acetate, washed with water (3 times) and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Chromatography (silica gel, hexanes to 1:1 hexanes : dichloromethane to 1:3:4 ethyl acetate : hexanes : dichloromethane to 3:1:4 ethyl acetate : hexanes : dichloromethane) afforded the title compound (1.35 g, 39%). ¹H NMR (CDCl₃) δ (ppm): 8.12 (m, 1H), 8.00 (m, 1H), 7.47 (m, 2H), 4.21 (m, 2H), 3.81 (m, 1H), 3.25 (m, 2H), 2.81 (m, 2H), 2.38 (bs, 1H), 1.50 (bs, 9H).

Example 22**2-[2-(3-chloro-phenyl)-2H-tetrazol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester**

A mixture of 2-(1H-tetrazol-5-yl)-piperidine-1-carboxylic acid tert-butyl ester or its 2H-tautomer (1 mmol) and tris-(3-chloro-phenyl)-bismuthane diacetate (1.2 mmol), cupric acetate (20mol%) and N,N,N',N'-tetramethylguanidine (2 mmol) in THF (10 mL) are heated at 50 °C for 18 h under an argon atmosphere. The solvent is removed in vacuo, and the product is purified using chromatography.

Example 23**2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidine**

Trifluoroacetic acid (5 mL) was added to 2-[5-(3-chloro-phenyl)-isoxazol-3-yl]-piperidine-1-carboxylic acid tert-butyl ester (500 mg, 1.38 mmol) in dichloromethane (5 mL) and the

mixture was stirred at room temperature for 1h, concentrated to dryness, and the residue was dissolved in sodium hydroxide (1N aqueous, 30 mL). The aqueous phase was extracted with dichloromethane (3X30 mL). The combined organic phase was washed with water (30 mL) and brine (30 mL), dried (sodium sulfate), filtered and concentrated *in vacuo* to give the title compound as light yellow oil (292 mg, 81%). ¹H NMR (CDCl₃), δ (ppm): 7.75 (dd, 1 H), 7.65 (m, 1 H), 7.41 (m, 2 H), 6.60 (s, 1H), 3.94 (dd, 1H), 3.17 (m, 1H), 2.83 (m, 1H), 2.35 (m, 1H), 2.00-1.53 (m, 6H).

Example 24

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-morpholine

Trifluoroacetic acid (2 mL) was added to 3-[5-(3-chloro-phenyl)-isoxazol-3-yl]-morpholine-4-carboxylic acid tert-butyl ester (236 mg, 0.65 mmol) in dichloromethane (2 mL). The mixture was stirred at room temperature for 1h, concentrated to dryness, and the residue was dissolved in sodium hydroxide (1N aqueous, 30 mL). The aqueous phase was extracted with dichloromethane (3X30 mL). The combined organic phase was washed with water (30 mL) and brine (30 mL), dried (sodium sulfate), filtered and concentrated *in vacuo* to yield the title compound as light yellow oil (171 mg, 99%). ¹H NMR (CDCl₃), δ (ppm): 7.72 (s, 1H), 7.62 (m, 1H), 7.37 (m, 2H), 6.59 (s, 1H), 4.18 (dd, 1H), 4.00 (dd, 1H), 3.87 (dt, 1H), 3.62 (m, 2H), 3.03 (m, 2H), 2.10 (bs, 1H).

Example 25

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholine

A solution of the 3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholine-4-carboxylic acid tert-butyl ester (783 mg, 2.19 mmol) was dissolved in a minimum amount of dichloromethane and then cooled to 0°C in an ice bath. A 1:1 solution of trifluoroacetic acid : dichloromethane (10 mL) was added and the mixture stirred at 0°C for 15 minutes, and the mixture was warmed to RT for 45 minutes. Ice cold water (20 mL) was added and the mixture was neutralized with saturated sodium bicarbonate. The product was extracted into dichloromethane (2 x 25 mL) and washed with brine (2 x 25 mL), dried over

anhydrous sodium sulfate, filtered and concentrated *in vacuo*. Chromatography (silica gel) yielded the title compound (429 mg, 74%). ¹H NMR (CDCl₃), δ (ppm): 8.11 (s, 1H), 8.00 (d, 1H), 7.47 (m, 2H), 3.6-4.4 (m, 6H), 3.0-3.3 (m, 2H).

Example 26

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidine

Trifluoroacetic acid (3 mL) is added to 2-[2-(3-chloro-phenyl)-2H-tetrazol-5-yl]-piperidine-1-carboxylic acid tert-butyl ester (1 mmol) in dichloromethane (3 mL) and the mixture is stirred at room temperature for 1h, concentrated to dryness, and the residue is dissolved in sodium hydroxide (1N aqueous, 15 mL). The aqueous phase is extracted with dichloromethane and the combined organic phase is washed with water and brine, dried (sodium sulfate), filtered and concentrated *in vacuo* to give the title compound. ¹H NMR (CDCl₃), δ (ppm): 8.19 (s, 1H), 8.06 (d, 1H), 7.48 (m, 2H), 4.20 (dd 1H), 3.24 (m, 1H), 2.88 (m, 1H), 2.18 (m, 1H) and 1.50-2.00 (m, 6H).

Example 27

2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidine-1-carbothioic acid methylamide

Methyl isothiocyanate (63 mg, 0.86 mmol) was added to 2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidine (150 mg, 0.57 mmol) in CH₂Cl₂ (4 mL) and the resulting mixture was stirred at room temperature for 12 h. The mixture was concentrated *in vacuo* and the isolated residue was triturated with 50% diethyl ether in hexanes to isolate the desired compound as off-white solid (quantative).

Example 28

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-morpholine-4-carbothioic acid methylamide

Methyl isothiocyanate (46.2 mg, 0.63 mmol) was added to 3-[5-(3-chloro-phenyl)-isoxazol-3-yl]-morpholine (145 mg, 0.55 mmol) in CHCl₃ (4 mL) and the resulting mixture was stirred at room temperature for 12 h. The mixture was concentrated *in vacuo* and the isolated residue was triturated with 50% diethyl ether in hexanes to isolate the title

compound as off-white solid (181 mg, 97%). ^1H NMR (CDCl_3), δ (ppm): 7.78 (m, 1H), 7.67 (m, 1H), 7.45 (m, 2H), 6.75 (s, 1H), 6.28 (m, 1H), 5.80 (m, 1H), 4.57 (d, 1H), 4.29 (d, 1H), 4.09 (dd, 1H), 3.99 (dd, 1H), 3.75 (dt, 1H), 3.45 (dt, 1H), 3.23 (d, 3H).

Example 29

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholine-4-carbothioic acid methylamide

Methyl isothiocyanate (161 mg, 2.2 mmol) and Et_3N (0.61 mg, 4.4 mmol) were added to a solution of 3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-morpholine (294 mg, 1.1 mmol) in CH_2Cl_2 (4 mL) and the mixture was stirred at room temperature for 12 h, and concentrated *in vacuo*. Chromatography gave the title compound as viscous oil (313 mg, 84%). ^1H NMR (CDCl_3), δ (ppm): 8.06 (d, 1 H), 7.96 (dd, 1H), 7.48 (dd, 1 H), 7.45 (t, 1 H), 6.88 (dd, 1H), 6.01 (br, m, 1H), 4.57 (d, 1H), 3.99 (m, 2H), 3.80 (m, 2H), 3.67 (ddd, 1H), 3.26 (d, 3H).

Example 30

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methylthiocarbamoyl-piperazine-1-carboxylic acid tert-butyl ester

Methyl isothiocyanate (256 mg, 3.50 mmol) was added to a solution of 3-[3-(3-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperazine-1-carboxylic acid tert-butyl ester (1.11 g, 3.04 mmol) in chloroform (17 mL) at room temperature. After stirring overnight, the mixture was concentrated and chromatography (silica gel, 1:3:4 ethyl acetate : hexanes : dichloromethane to 1.5:2.5:4 ethyl acetate : hexanes : dichloromethane) afforded the title compound (796 mg, 60%). ^1H NMR (CDCl_3) δ (ppm): 8.05 (m, 1H), 7.95 (m, 1H), 7.45 (m, 2H), 6.01 (m, 1H), 4.68 (m, 1H), 4.22 (m, 1H), 3.80 (m, 2H), 3.51 (m, 1H), 3.25 (m, 3H), 3.07 (m, 1H), 1.30 (bs, 9H).

Example 31**2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidine-1-carbothioic acid methylamide**

2-({2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}methyl)pyridine (600mg, 2.38 mmoles) was mixed with methyl isothiocyanate (250 mg, 3.41 mmol) in chloroform (10 mL) at room temperature overnight. The reaction mixture was concentrated and triturated with ether to give the title compound as a white solid (676 mg, 88 %). ¹H NMR (CDCl₃), δ (ppm): 8.13 (s, 1H), 8.03 (m, 1H), 7.51 (m, 2H), 6.93 (w, 1H), 6.06 (w, 1H), 4.24 (m 1H), 3.34 (m, 1H), 3.23 (d, 3H), 2.46 (m, 1H), 2.11 (m, 1H), 1.60-1.95 (m, 4H).

Example 32**2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester**

Iodomethane (50 µl, 0.80 mmol) was added to 2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidine-1-carbothioic acid methylamide (181 mg, 0.54 mmol) in methanol (4 mL) and the resulting mixture was stirred at 75°C for 3h. The mixture was cooled to room temperature, diluted with saturated sodium bicarbonate (aqueous, 30 mL), extracted with dichloromethane (3X20 mL). The combined organic phase was washed with brine (30 mL), dried (sodium sulfate), filtered and concentrated *in vacuo* to yield the title compound as yellow oil (0.19 g, 100%). ¹H NMR (CDCl₃), δ (ppm): 7.73 (dd, 1H), 7.64 (m, 1H), 7.38 (m, 2H), 6.60 (s, 1H), 5.37 (m, 1H), 4.25 (m, 1H), 3.95 (m, 2H), 3.67 (m, 2H), 3.32 (m, 1H), 3.25 (s, 3H), 2.36 (s, 3H).

Example 33**3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-N-methyl-morpholine-4-carboximidothioic acid methyl ester**

Iodomethane (50 µl, 0.80 mmol) was added to 3-[5-(3-chloro-phenyl)-isoxazol-3-yl]-morpholine-4-carbothioic acid methylamide (181 mg, 0.54 mmol) in methanol (4 mL) and the resulting mixture was stirred at 75°C for 3h. The mixture was cooled to room temperature, diluted with saturated sodium bicarbonate (aqueous, 30 mL), extracted with

dichloromethane (3X20 mL). The combined organic phase was washed with brine (30 mL), dried (sodium sulfate), filtered and concentrated *in vacuo* to yield the title compound as yellow oil (0.19 g, 100%). ¹H NMR (CDCl₃), δ (ppm): 7.73 (dd, 1H), 7.64 (m, 1H), 7.38 (m, 2H), 6.60 (s, 1H), 5.37 (m, 1H), 4.25 (m, 1H), 3.95 (m, 2H), 3.67 (m, 2H), 3.32 (m, 1H), 3.25 (s, 3H), 2.36 (s, 3H).

Example 34

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-methylmorpholine-4-carboximidothioic acid methyl ester

Iodomethane (212 mg, 1.5 mmol) was added to a solution of 3-[3-(3-chloro-phenyl)[1,2,4]oxadiazol-5-yl]-morpholine-4-carbothioic acid methylamide (313 mg, 0.92 mmol) in methanol (10 mL) and the mixture was stirred at 75°C for 3h. The mixture was cooled to room temperature, diluted with saturated sodium bicarbonate (aqueous, 30 mL), extracted with dichloromethane (3X20 mL). The combined organic phase was washed with brine (30 mL), dried (sodium sulfate), filtered and concentrated *in vacuo* to yield the title compound as a white solid (248 mg, 76%). ¹H NMR (CDCl₃), δ (ppm) 8.08 (d, 1 H), 7.95 (dd, 1H), 7.47 (dd, 1 H), 7.43 (t, 1 H), 5.47 (dd, 1H), 4.36 (d, 1H), 3.40-4.00 (m, 5H), 3.21 (s, 3H), 2.36 (s, 3H).

Example 35

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(methylimino-methylsulfanyl-methyl)-piperazine-1-carboxylic acid tert-butyl ester

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methylthiocarbamoyl-piperazine-1-carboxylic acid tert-butyl ester (796 mg, 1.82 mmol) and iodomethane (0.170 mL, 2.73 mmol) in methanol (11 mL) were heated at 75°C in a sealed vial for 2 hours. After cooling, the mixture was concentrated and then the residue was dissolved with dichloromethane. The organic layer was washed with saturated sodium bicarbonate, dried over anhydrous sodium sulfate, filtered, and concentrated. Chromatography (silica gel, 25% ethyl acetate in hexanes) afforded the title compound (632 mg, 77%). ¹H NMR

(CDCl₃) δ (ppm): 8.08 (m, 1H), 7.97 (m, 1H), 7.44 (m, 2H), 5.51 (m, 1H), 4.49 (m, 1H), 4.01 (m, 2H), 3.49 (m, 2H), 3.20 (s, 3H), 3.15 (m, 1H), 2.37 (s, 3H), 1.38 (bs, 9H).

Example 36

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidine-1-carbothioic acid methylamide (676 mg, 2.0 mmol) was mixed with iodomethane (0.4 mL) in methanol (15 mL) in a sealed vial at 80 °C for 2 hours. The reaction mixture was concentrated by rotavapor. The residue was basified with saturated sodium bicarbonate and extracted with dichloromethane. The organic layer was dried with MgSO₄ to give the title compound as a sticky pale-yellow oil (700 mg, 100 %). ¹H NMR (CDCl₃), δ (ppm): 8.15 (s, 1H), 8.04 (d, 1H), 7.48 (m, 2H), 5.75 (m, 1H), 3.22 (m, 1H), 3.22 (m,s, 4H), 2.04 (s,m, 4H), 2.10 (m, 1H), 1.69 (m, 4H).

Example 37

4-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidin-1-yl}-4-methyl-4H [1,2,4]triazol-3-yl)-pyridine

Isonicotinic acid hydrazide (42.3 mg, 0.31 mmol) was added to 2-[5-(3-Chloro-phenyl)-isoxazol-3-yl] N-methyl-piperidine-1-carboximidothioic acid methyl ester (90mg, 0.26 mmol) in ethanol (1.5 mL). The mixture was stirred at 75°C for 12 h, and then diluted with dichloromethane (8 mL). The organic phase was sequentially washed with water (4X10 mL) and brine (10 mL), dried (sodium sulfate), filtered and concentrated *in vacuo*.

Chromatography (silica gel, 10% methanol in ethyl acetate) gave a yellow oil that was triturated with 30% hexanes in diethyl ether to yield the title compound as an off-white solid (50 mg). ¹H NMR (CDCl₃), δ (ppm): 8.72 (d, 2H), 7.69 (s, 1H), 7.59 (m, 3H), 7.36 (m, 2H), 6.54 (s, 1H), 4.79 (dd, 1H), 3.64 (s, 3H), 3.28 (m, 2H), 2.20 (m, 2H), 1.90-1.73 (m, 4H).

Example 38**3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine**

Isonicotinic acid hydrazide (56.1 mg, 0.41 mmol) was added to 3-[5-(3-chloro-phenyl)-isoxazol-3-yl]-N-methyl-morpholine-4-carboximidothioic acid methyl ester (96 mg, 0.27 mmol) in ethanol. The resulting mixture was left stirring at 75°C for 12 h, and then diluted with dichloromethane (8 mL). The organic phase was sequentially washed with water (4X10 mL) and brine (10 mL), dried (sodium sulfate), filtered and concentrated *in vacuo*. Chromatography (silica gel, 10% methanol in ethyl acetate) gave a yellow oil that was triturated with 30% hexanes in diethyl ether to yield the title compound as an off-white solid (46 mg). ¹H NMR (CDCl₃), δ (ppm): 8.76 (d, 2H), 7.72 (dd, 1H), 7.62 (m, 3H), 7.42 (m, 2H), 6.67 (s, 1H), 4.82 (dd, 1H), 4.25 (dd, 1H), 4.07 (m, 3H), 3.71 (s, 3H), 3.45 (m, 2H).

Example 39**3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine**

Pyridine (30 µl) and 4-difluoromethoxy-benzoic acid hydrazide (57.9mg, 0.29 mmol) were added to a solution of 3-[5-(3-chloro-phenyl)-isoxazol-3-yl]-N-methyl-morpholine-4-carboximidothioic acid methyl ester (960mg, 0.27 mmol) in ethanol. The mixture was stirred at 75°C for 48 h, and then diluted with dichloromethane (8 mL). The organic phase was sequentially washed with water (4X10 mL) and brine (10 mL), dried (sodium sulfate), filtered and concentrated *in vacuo*. Chromatography (silica gel, 10% dichloromethane in ethyl acetate) yielded the title compound as clear oil (18mg). ¹H NMR (CDCl₃), δ (ppm): 7.67 (m, 4H), 7.39 (m, 2H), 7.23 (d, 2H), 6.66 (s, 1H), 6.58 (t, 1H), 4.80 (dd, 1H), 4.25 (dd, 1H), 4.07 (m, 3H), 3.61 (s, 3H), 3.40 (m, 2H).

Example 40**3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine**

Pyridine (30 μ l) and isonicotinic acid hydrazide (60 mg, 0.29 mmol) were added to 3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-methylmorpholine-4-carboximidothioic acid methyl ester (101mg, 0.44 mmol) in ethanol, and the mixture was stirred at 75°C for 48 h, and the mixture was diluted with dichloromethane (8 mL). The organic phase was sequentially washed with water (4X10 mL) and brine (10 mL), dried (sodium sulfate), filtered and concentrated *in vacuo*. Chromatography (silica gel, 10% dichloromethane in ethyl acetate) yielded the title compound as clear oil (40mg, 33%). ^1H NMR (CDCl_3), δ (ppm): 8.78 (d, 2 H), 8.03 (d, 1 H), 7.92 (dd, 1H), 7.63 (d, 2 H), 7.46 (dd, 1 H), 7.40 (t, 1H), 5.14 (dd, 1H), 4.35 (d, 1H), 4.14 (m, 3H), 3.75 (s, 3H), 3.73 (m, 1H), 3.39 (m, 1H).

Example 41**3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine**

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-N-methyl-morpholine-4-carboximidothioic acid methyl ester (100 mg, 0.28 mmol), 4-difluoromethoxy-benzoic acid hydrazide (60.2 mg, 0.30 mmol) and pyridine (4 drops) in ethanol (10 mL) were heated at 75°C for 24 hours. After cooling, the reaction mixture was diluted with ethyl acetate and then washed with water (5 times) and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Chromatography (silica gel, 1–2% methanol in dichloromethane) afforded the title compound (99.5 mg, 73%). ^1H NMR (CDCl_3) δ (ppm): 8.03 (m, 1H), 7.93 (m, 1H), 7.67 (m, 2H), 7.46 (m, 1H), 7.42 (m, 1H), 7.25 (m, 2H), 6.59 (t, 1H), 5.13 (m, 1H), 4.37 (m, 1H), 4.16 (m, 1H), 4.01 (m, 2H), 3.66 (m, 1H), 3.67 (s, 3H), 3.36 (m, 1H).

Example 42**3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine-1-carboxylic acid tert-butyl ester**

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(methylimino-methylsulfanyl-methyl)-piperazine-1-carboxylic acid tert-butyl ester (211.6 mg, 0.47 mmol) and isonicotinic hydrazide (96.5 mg, 0.70 mmol) in ethanol (6 mL) were heated at 80°C for 24 hours. After cooling, the mixture was diluted with ethyl acetate and washed with water (5 times) and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Chromatography (silica gel, 0–5% 2M methanolic ammonia in 1:1 ethyl acetate : dichloromethane) afforded the title compound (168.5 mg, 69%, colorless oil). ¹H NMR (CDCl₃) δ (ppm): 8.77 (m, 2H), 8.04 (s, 1H), 7.94 (m, 1H), 7.62 (m, 2H), 7.44 (m, 2H), 5.08 (m, 1H), 4.15 (m, 1H), 4.06 (m, 1H), 3.75 (m, 3H), 3.73 (s, 3H), 3.32 (m, 1H), 1.43 (bs, 9H).

Example 43**2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-(4-methyl-5-pyridin-4-yl-4H-1,2,4]triazol-3-yl)-piperazine**

Trifluoroacetic acid (1.5mL) was added to a solution of 3-[3-(3-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine-1-carboxylic acid tert-butyl ester (164 mg, 0.31 mmol) in dichloromethane (3 mL) at 0°C and stirred for 2.5 hours. After the mixture was concentrated, the residue was diluted with dichloromethane and then washed with saturated sodium bicarbonate, dried over anhydrous sodium sulfate, filtered and concentrated to afford the title compound (109 mg, 83 %, white foam solid). ¹H NMR (CDCl₃) δ (ppm): 8.75 (m, 2H), 8.02 (m, 1H), 7.93 (m, 1H), 7.62 (m, 2H), 7.43 (m, 2H), 5.01 (m, 1H), 3.73 (s, 3H), 3.62 (m, 2H), 3.40 (m, 1H), 3.22 (m, 3H).

Example 44**2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-1-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine**

Formic acid (0.1 mL), formaldehyde (37 wt.% solution in water, 0.1 mL) and sodium cyanoborohydride (1.0 M in THF, 0.1 mL) were added to a solution of 2-[3-(3-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine (50.3 mg, 0.12 mmol) in methanol (0.8 mL) at room temperature. After stirring for 30 minutes, the mixture was diluted with water and extracted with chloroform (4 times), dried over anhydrous sodium sulfate, filtered and concentrated. Chromatography (silica gel, 1–5% 2M methanolic ammonia in dichloromethane) afforded the title compound (90%). ¹H NMR (CDCl₃) δ (ppm): 8.77 (m, 2H), 8.03 (m, 1H), 7.93 (m, 1H), 7.63 (m, 2H), 7.42 (m, 2H), 5.21 (m, 1H), 3.74 (s, 3H), 3.70 (m, 1H), 3.43 (m, 1H), 3.09 (m, 2H), 2.70 (m, 2H), 2.41 (s, 3H).

Example 45**3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine-1-carboxylic acid tert-butyl ester**

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(methylimino-methylsulfanyl-methyl)-piperazine-1-carboxylic acid tert-butyl ester (211.3 mg, 0.47 mmol), 4-difluoromethoxy-benzoic acid hydrazide (99.2 mg, 0.49 mmol) and pyridine (8 drops) in ethanol were heated at 75°C for three days. After cooling, the reaction mixture was diluted with ethyl acetate and then washed with water (5 times) and brine, dried over anhydrous sodium sulfate, filtered and concentrated. Chromatography (silica gel, ethyl acetate : hexanes : dichloromethane 3:1:4 to 100% ethyl acetate) afforded the title compound.

Example 46**2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine**

Trifluoroacetic acid (1.5mL) was added to a solution of 3-[3-(3-chloro-phenyl)-

[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine-1-carboxylic acid tert-butyl ester at 0°C and stirred for 2.5 hours. After the mixture was concentrated, the residue was diluted with dichloromethane and then washed with saturated sodium bicarbonate, dried over anhydrous sodium sulfate filtered, and concentrated. Chromatography (silica gel, 3-4% 2M methanolic ammonia in dichloromethane) afforded the titled compound (white solid, 31% yield over 2 steps). ¹H NMR (CDCl₃) δ (ppm): 8.05 (m, 1H), 7.95 (m, 1H), 7.69 (m, 2H), 7.47 (m, 1H), 7.42 (m, 1H), 7.26 (m, 2H), 6.59 (t, 1H), 5.01 (m, 1H), 3.63 (m, 5H), 3.39 (m, 1H), 3.20 (m, 3H).

Example 47

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-4-methyl-piperazine

Formic acid (0.1 mL), formaldehyde (37 wt.% in water, 0.1 mL) and sodium cyanoborohydride (1.0M in THF, 0.1 mL) were added to a solution of 2-[3-(3-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine (27.3 mg, 0.056 mmol) in methanol (0.8 mL) at room temperature. After stirring for 30 minutes, the mixture was diluted with water and extracted with chloroform (3 times), dried over anhydrous sodium sulfate, filtered and concentrated. Chromatography (silica gel, 1 – 3% methanol in dichloromethane) afforded the titled compound (57%). ¹H NMR (CDCl₃) δ (ppm): 8.03 (m, 1H), 7.93 (m, 1H), 7.68 (m, 2H), 7.46 (m, 1H), 7.42 (m, 1H), 7.25 (m, 2H), 6.59 (t, 1H), 5.20 (m, 1H), 3.68 (m, 1H), 3.66 (s, 3H), 3.40 (m, 1H), 3.12 (m, 1H), 3.02 (m, 1H), 2.69 (m, 2H), 2.40 (s, 3H).

Example 48

2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester (70 mg, 0.2 mmol) was mixed with 4-difluoromethoxy-benzoic acid hydrazide (40.4 mg, 0.2 mmol) in ethanol at 80 °C overnight. The reaction mixture was diluted with

water and extracted with dichloromethane. The dichloromethane layer was dried and purified by chromatography (ethyl acetate) to give the title compound (37 mg, 38%). ¹H NMR (CDCl₃), δ (ppm): 8.09 (s, 1H), 7.99 (m, 1H), 7.66 (d, 2H), 7.46 (m, 2H), 7.24 (d, 2H), 6.58 (t, 1H), 5.10 (m, 1H), 3.66 (s, 3H), 3.48 (m, 1H), 3.30 (m, 1H), 1.70-2.30 (m, 6H).

Example 49

4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester (70 mg, 0.2 mmol) was mixed with isonicotinic acid hydrazide (33.2 mg, 0.2 mmol) in ethanol at 80 °C overnight. The reaction mixture was diluted with water and extracted with dichloromethane. The dichloromethane layer was dried and purified by chromatography (ethyl acetate) to give the title compound (34 mg, 40.3%). ¹H NMR (CDCl₃), δ (ppm): 8.74 (d, 2H), 8.07 (s, 1H), 7.96 (m, 1H), 7.61 (d, 2H), 7.45 (m, 2H), 5.11 (m, 1H), 3.73 (s, 3H), 3.48 (m, 1H), 3.30 (m, 1H), 1.70-2.30 (m, 6H).

Example 50

2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-[5-(4-methoxyphenyl)-4-methyl-4H-1,2,4-triazol-3-yl]piperidine

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester (70 mg, 0.2 mmol) was mixed with 4-methoxy-benzoic acid hydrazide (33.2 mg, 0.2 mmol) in ethanol at 80 °C overnight. The reaction mixture was diluted with water and extracted with dichloromethane. The dichloromethane layer was dried and purified by chromatography (ethyl acetate) to give the title compound (20.2 mg, 22.4%). ¹H NMR (CDCl₃), δ (ppm): 8.09 (s, 1H), 7.98 (m, 1H), 7.57 (d, 2H), 7.45 (m, 2H), 7.99 (d, 2H), 5.10 (m, 1H), 3.86 (s, 3H), 3.63 (s, 3H), 3.48 (m, 1H), 3.29 (m, 1H), 1.70-2.30 (m, 6H).

Example 51**[4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)phenyl]dimethylamine**

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester (70 mg, 0.2 mmol) was mixed with 4-methoxy-benzoic acid hydrazide (27.4 mg, 0.2 mmol) in ethanol at 80 °C overnight. The reaction mixture was diluted with water and extracted with dichloromethane. The dichloromethane layer was dried and purified by chromatography (ethyl acetate) to give the title compound (20.2 mg, 21.6%). ¹H NMR (CDCl₃), δ (ppm): 8.10 (s, 1H), 7.97 (m, 1H), 7.48 (m, 4H), 6.75 (d, 2H), 5.09 (m, 1H), 3.63 (s, 3H), 3.48 (m, 1H), 3.29 (m, 1H), 3.02 (s, 3H), 1.70-2.30 (m, 6H).

Example 52**[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-benzyl]-dimethyl-amine**

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester (49.9 mg, 0.1422 mmol) was mixed with 4-dimethylaminomethyl-benzoic acid hydrazide (30 mg, 0.156 mmol) in ethanol (1.2 mL) at 100 °C overnight. The reaction mixture was diluted with ethyl acetate, washed with water x 3, purified by chromatography with (2~3 % 2M methanolic ammonia in chloroform) to give the title compound (9.2 mg, 13.5%) as an off-white solid. ¹H NMR (CDCl₃), δ (ppm): 8.09 (s, 1H), 7.98 (m, 1H), 7.60 (d, 2H), 7.45 (m, 4H), 5.11 (m, 1H), 3.66 (s, 3H), 3.48 (s plus m, 3H), 3.30 (m, 1H), 2.28 (s, 6H), 1.60~2.20 (m, 6H).

Example 53**{2-[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-[1,2,4]triazol-3-yl)-phenoxy]-ethyl}-dimethyl-amine**

2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-N-methyl-piperidine-1-carboximidothioic acid methyl ester (85 mg, 0.242 mmol) was mixed with 4-(2-dimethylamino-ethoxy)-benzoic acid hydrazide (75.7 mg, 0.339 mmol) in ethanol (1.2 mL) at 100 °C overnight. The

reaction mixture was diluted with dichloromethane, washed with water (x3), purified by chromatography (2~3 % 2M methanolic ammonia in chloroform) to give the title compound (32 mg, 26%) as a yellow sticky oil. ¹H NMR (CDCl₃), δ (ppm): 8.09 (s, 1H), 7.97 (m, 1H), 7.56 (d, 2H), 7.44 (m, 2H), 7.01 (d, 2H), 5.09 (m, 1H), 4.11 (t, 2H), 3.62 (s, 3H), 3.65 (m, 1H), 3.44 (m, 1H), 2.76 (t, 2H), 2.36 (s, 6H), 1.60~2.30 (m, 6H).

Examples 54a and 54b

(R)-3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine and

(S) 3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine

The two enantiomers were isolated from racemic 3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine using chiral HPLC column (Chiralpak AD) with Hexane/Isopropanol (20 : 80); Enantiomer 1 has retention time of 7.5 minutes whereas Enantiomer 2 has retention time of 8.7 minutes.

Examples 55a and 55b

(R)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine

(S)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine

2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine was separated by Chiralpak AD (4.6 X 250) with ethanol:isopropanol(1:1) at 1.0 mL/min flow rate to give two enantiomers 13.3 mg (R_t = 14.2 min) and 11.9 mg (R_t = 18.7 min).

Examples 56a and 56b

(R)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

(S)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

The product was separated by Chiralpak AD (4.6 X 250) with ethanol:isopropanol (1:1) at 1.0 mL/min flow rate to give two enantiomers 9.5 mg (R_t = 11.6 min) and 10.8 mg (R_t = 16.8 min).

Pharmacology

The pharmacological properties of the compounds of the invention can be analyzed using standard assays for functional activity. Examples of glutamate receptor assays are well known in the art as described in for example Aramori *et al.*, *Neuron* 8:757 (1992), Tanabe *et al.*, *Neuron* 8:169 (1992), Miller *et al.*, *J. Neuroscience* 15: 6103 (1995), Balazs, *et al.*, *J. Neurochemistry* 69:151 (1997). The methodology described in these publications is incorporated herein by reference. Conveniently, the compounds of the invention can be studied by means of an assay that measures the mobilization of intracellular calcium, $[Ca^{2+}]_i$ in cells expressing mGluR5.

For FLIPR analysis, cells expressing human mGluR5d as described in WO97/05252 were seeded on collagen coated clear bottom 96-well plates with black sides and analysis of $[Ca^{2+}]_i$ mobilization was done 24 h after seeding.

FLIPR experiments were done using a laser setting of 0.800 W and a 0.4 second CCD camera shutter speed. Each FLIPR experiment was initiated with 160 μ L of buffer present in each well of the cell plate. After each addition of the compound, the fluorescence signal was sampled 50 times at 1 second intervals followed by 3 samples at 5 second intervals. Responses were measured as the peak height of the response within the sample period. EC_{50} and IC_{50} determinations were made from data obtained from 8-point concentration response curves (CRC) performed in duplicate. Agonist CRC were generated by scaling all responses to the maximal response observed for the plate. Antagonist block of the agonist

challenge was normalized to the average response of the agonist challenge in 14 control wells on the same plate.

We have validated a secondary functional assay for mGluR5d as described in WO97/05252 based on Inositol Phosphate (IP₃) turnover. IP₃ accumulation is measured as an index of receptor mediated phospholipase C turnover. GHEK cells stably expressing the human mGluR5d receptors were incubated with [3H] myo-inositol overnight, washed three times in HEPES buffered saline and pre-incubated for 10 min with 10 mM LiCl. Compounds (agonists) were added and incubated for 30 min at 37°C. Antagonist activity was determined by pre-incubating test compounds for 15 min, then incubating in the presence of glutamate (80 μM) or DHPG (30 μM) for 30 min. Reactions were terminated by the addition of perchloric acid (5%). Samples were collected and neutralized, and inositol phosphates were separated using Gravity-Fed Ion-Exchange Columns.

A detailed protocol for testing the compounds of the invention is provided in the assay below.

Assay of Group I receptor antagonist activity

For FLIPR analysis, cells expressing human mGluR5d as described in WO97/05252 were seeded on collagen coated clear bottom 96-well plates with black sides and analysis of [Ca²⁺]_i mobilization was performed 24 h following seeding. Cell cultures in the 96-well plates were loaded with a 4 μM solution of acetoxymethyl ester form of the fluorescent calcium indicator fluo-3 (Molecular Probes, Eugene, Oregon) in 0.01% pluronic. All assays were performed in a buffer containing 127 mM NaCl, 5 mM KCl, 2 mM MgCl₂, 0.7 mM NaH₂PO₄, 2 mM CaCl₂, 0.422 mg/ml NaHCO₃, 2.4 mg/ml HEPES, 1.8 mg/ml glucose and 1 mg/ml BSA Fraction IV (pH 7.4).

FLIPR experiments were done using a laser setting of 0.800 W and a 0.4 second CCD camera shutter speed with excitation and emission wavelengths of 488 nm and 562 nm, respectively. Each FLIPR experiment was initiated with 160 μl of buffer present in each well of the cell plate. A 40 μl addition from the antagonist plate was followed by a 50 μL addition from the agonist plate. After each addition the fluorescence signal was sampled 50

times at 1 second intervals followed by 3 samples at 5 second intervals. Responses were measured as the peak height of the response within the sample period.

EC₅₀/IC₅₀ determinations were made from data obtained from 8 points concentration response curves (CRC) performed in duplicate. Agonist CRC were generated by scaling all responses to the maximal response observed for the plate. Antagonist block of the agonist challenge was normalized to the average response of the agonist challenge in 14 control wells on the same plate.

Measurement of Inositol Phosphate Turnover in Intact Whole Cells

GHEK stably expressing the human mGluR5d receptor were seeded onto 24 well poly-L-lysine coated plates at 40×10^4 cells /well in media containing 1 μ Ci/well [³H] myo-inositol. Cells were incubated overnight (16 h), then washed three times and incubated for 1 h at 37°C in HEPES buffered saline (146 mM NaCl, 4.2 mM KCl, 0.5 mM MgCl₂, 0.1% glucose, 20 mM HEPES, pH 7.4) supplemented with 1 unit/ml glutamate pyruvate transaminase and 2 mM pyruvate. Cells were washed once in HEPES buffered saline and pre-incubated for 10 min in HEPES buffered saline containing 10 mM LiCl. Compounds (agonists) were added and incubated at 37°C for 30 min. Antagonist activity was determined by pre-incubating test compounds for 15 min, then incubating in the presence of glutamate (80 μ M) or DHPG (30 μ M) for 30 min. The reaction was terminated by the addition of 0.5 ml perchloric acid (5%) on ice, with incubation at 4°C for at least 30 min. Samples were collected in 15 ml Falcon tubes and inositol phosphates were separated using Dowex columns, as described below.

Assay For Inositol Phosphates Using Gravity-Fed Ion-Exchange Columns

Preparation of Ion- Exchange Columns

Ion-exchange resin (Dowex AG1-X8 formate form, 200-400 mesh, BIORAD) was washed three times with distilled water and stored at 4°C. 1.6 ml resin was added to each column, and washed with 3 ml 2.5 mM HEPES, 0.5 mM EDTA, pH 7.4.

a) Sample Treatment

Samples were collected in 15 ml Falcon tubes and neutralized with 0.375 M HEPES, 0.75 M KOH. 4 ml of HEPES / EDTA (2.5 / 0.5 mM, pH 7.4) were added to precipitate the potassium perchlorate. Supernatant was added to the prepared Dowex columns.

b) Inositol Phosphate Separation

Elute glycerophosphatidyl inositols with 8 ml 30 mM ammonium formate.

Elute total inositol phosphates with 8 ml 700 mM ammonium formate / 100 mM formic acid and collect eluate in scintillation vials. Count eluate mixed with 8 ml scintillant.

One aspect of the invention relates to a method for inhibiting activation of mGluR 5, comprising treating a cell containing said receptor with an effective amount of the compound of formula I.

Screening for compounds active against tlesr

Adult Labrador retrievers of both genders, trained to stand in a Pavlov sling, are used. Mucosa-to-skin esophagostomies are formed and the dogs are allowed to recover completely before any experiments are done.

Motility measurement

In brief, after fasting for approximately 17 h with free supply of water, a multilumen sleeve/sidehole assembly (Dentsleeve, Adelaide, South Australia) is introduced through the esophagostomy to measure gastric, lower esophageal sphincter (LES) and esophageal pressures. The assembly is perfused with water using a low-compliance manometric perfusion pump (Dentsleeve, Adelaide, South Australia). An air-perfused tube is passed in the oral direction to measure swallows, and an antimony electrode monitored pH, 3 cm above the LES. All signals are amplified and acquired on a personal computer at 10 Hz.

When a baseline measurement free from fasting gastric/LES phase III motor activity has been obtained, placebo (0.9% NaCl) or test compound is administered intravenously (i.v., 0.5 ml/kg) in a foreleg vein. Ten min after i.v. administration, a nutrient meal (10% peptone, 5% D-glucose, 5% Intralipid, pH 3.0) is infused into the stomach through the

central lumen of the assembly at 100 ml/min to a final volume of 30 ml/kg. The infusion of the nutrient meal is followed by air infusion at a rate of 500 ml/min until an intragastric pressure of 10 ± 1 mmHg is obtained. The pressure is then maintained at this level throughout the experiment using the infusion pump for further air infusion or for venting air from the stomach. The experimental time from start of nutrient infusion to end of air insufflation is 45 min. The procedure has been validated as a reliable means of triggering TLESRs.

TLESRs is defined as a decrease in lower esophageal sphincter pressure (with reference to intragastric pressure) at a rate of >1 mmHg/s. The relaxation should not be preceded by a pharyngeal signal ≤ 2 s before its onset in which case the relaxation is classified as swallow-induced. The pressure difference between the LES and the stomach should be less than 2 mmHg, and the duration of the complete relaxation longer than 1 s.

Abbreviations


BSA	Bovine Serum Albumin
CCD	Charge Coupled Device
CRC	Concentration Response Curve
DHPG	3,5-dihydroxyphenylglycine;
EDTA	Ethylene Diamine Tetraacetic Acid
FLIPR	Fluorometric Imaging Plate reader
GHEK	GLAST-containing Human Embryonic Kidney
GLAST	glutamate/aspartate transporter
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (buffer)
IP ₃	inositol triphosphate

Results

Typical IC₅₀ values as measured in the assays described above are 10 μ M or less. In one aspect of the invention the IC₅₀ is below 2 μ M. In another aspect of the invention the IC₅₀ is below 0.2 μ M. In a further aspect of the invention the IC₅₀ is below 0.05 μ M.

WE CLAIM,

1. A compound according to formula I



wherein

P is selected from aryl and heteroaryl;

R^1 is attached to P via a carbon atom on ring P and is selected from the group consisting of: hydroxy, halo, nitro, C_{1-6} alkylhalo, OC_{1-6} alkylhalo, C_{1-6} alkyl, OC_{1-6} alkyl, C_{2-6} alkenyl, OC_{2-6} alkenyl, C_{2-6} alkynyl, OC_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, OC_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylaryl, OC_{0-6} alkylaryl, CHO, $(CO)R^5$, $O(CO)R^5$, $O(CO)OR^5$, $O(CNR^5)OR^5$, C_{1-6} alkyl OR^5 , OC_{2-6} alkyl OR^5 , C_{1-6} alkyl $(CO)R^5$, OC_{1-6} alkyl $(CO)R^5$, C_{0-6} alkyl CO_2R^5 , OC_{1-6} alkyl CO_2R^5 , C_{0-6} alkylcyano, OC_{2-6} alkylcyano, C_{0-6} alkyl NR^5R^6 , OC_{2-6} alkyl NR^5R^6 , C_{1-6} alkyl $(CO)NR^5R^6$, OC_{1-6} alkyl $(CO)NR^5R^6$, C_{0-6} alkyl $NR^5(CO)R^6$, OC_{2-6} alkyl $NR^5(CO)R^6$, C_{0-6} alkyl $NR^5(CO)NR^5R^6$, C_{0-6} alkyl SR^5 , OC_{2-6} alkyl SR^5 , C_{0-6} alkyl $(SO)R^5$, OC_{2-6} alkyl $(SO)R^5$, C_{0-6} alkyl SO_2R^5 , OC_{2-6} alkyl SO_2R^5 , C_{0-6} alkyl $(SO_2)NR^5R^6$, OC_{2-6} alkyl $(SO_2)NR^5R^6$, C_{0-6} alkyl $NR^5(SO_2)R^6$, OC_{2-6} alkyl $NR^5(SO_2)R^6$, C_{0-6} alkyl $NR^5(SO_2)NR^5R^6$, OC_{2-6} alkyl $NR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $O(CO)NR^5R^6$, NR^5OR^6 , C_{0-6} alkyl $NR^5(CO)OR^6$, OC_{2-6} alkyl $NR^5(CO)OR^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

X^1 is selected from the group consisting of: N, NR^4 and CR^4 ;

X^2 is selected from the group consisting of: C and N;

X^3 is selected from the group consisting of: CR^4 , N and O;

X^4 is selected from the group consisting of: CR^4 , N, NR^4 and O;

X^5 is selected from the group consisting of: a bond, $CR^4R^{4'}$, NR^4 , O, S, SO and SO_2 ;

X^6 is selected from the group consisting of: CR^4 and N;

X^7 is selected from the group consisting of: C and N;

R^4 is independently selected from a group consisting of hydrogen, hydroxy, C_{1-6} alkyl, C_{0-6} alkylcyano, oxo, $=NR^5$, $=NOR^5$, C_{1-4} alkylhalo, halo, C_{3-7} cycloalkyl, $O(CO)C_{1-4}$ alkyl, C_{1-4} alkyl(SO) C_{0-4} alkyl, C_{1-4} alkyl(SO_2) C_{0-4} alkyl, (SO) C_{0-4} alkyl, (SO_2) C_{0-4} alkyl, OC_{1-4} alkyl, C_{1-4} alkyl OR^5 and C_{0-4} alkyl NR^5R^6 ;

Q is selected the group consisting of heterocycloalkyl and heteroaryl;

R^2 and R^3 are independently selected from the group consisting of: hydroxy, C_{0-6} alkylcyano, oxo, $=NR^5$, $=NOR^5$, C_{1-4} alkylhalo, halo, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{0-6} alkylaryl, C_{0-6} alkylheteroaryl, C_{1-6} alkylcycloalkyl, C_{0-6} alkylheterocycloalkyl, OC_{1-4} alkyl, OC_{0-6} alkylaryl, $O(CO)C_{1-4}$ alkyl, (CO) OC_{1-4} alkyl, C_{0-4} alkyl(S) C_{0-4} alkyl, C_{1-4} alkyl(SO) C_{0-4} alkyl, C_{1-4} alkyl(SO_2) C_{0-4} alkyl, (SO) C_{0-4} alkyl, (SO_2) C_{0-4} alkyl, C_{1-4} alkyl OR^5 , C_{0-4} alkyl NR^5R^6 and a 5- or 6-membered ring containing atoms independently selected from C, N, O and S, which ring may optionally be fused with a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N and O and wherein said ring and said fused ring may be substituted by one or more A;

wherein any C_{1-6} alkyl, aryl, or heteroaryl defined under R^1 , R^2 and R^3 may be substituted by one or more A ;

A is selected from the group consisting of: hydrogen, hydroxy, halo, nitro, oxo, C_{0-6} alkylcyano, C_{0-4} alkyl C_{3-6} cycloalkyl, C_{1-6} alkyl, $-OC_{1-6}$ alkyl, C_{1-6} alkylhalo, OC_{1-6} alkylhalo, C_{2-6} alkenyl, C_{0-3} alkylaryl, C_{0-6} alkyl OR^5 , OC_{2-6} alkyl OR^5 , C_{0-6} alkyl SR^5 , OC_{2-6} alkyl SR^5 , (CO) R^5 , $O(CO)R^5$, OC_{2-6} alkylcyano, OC_{1-6} alkyl CO_2R^5 , $O(CO)OR^5$, OC_{1-6} alkyl(CO) R^5 , C_{1-6} alkyl(CO) R^5 , NR^5OR^6 , $C_{0-6}NR^5R^6$, OC_{2-6} alkyl NR^5R^6 , C_{0-6} alkyl(CO) NR^5R^6 , OC_{1-6} alkyl(CO) NR^5R^6 , OC_{2-6} alkyl $NR^5(CO)R^6$, C_{0-6} alkyl $NR^5(CO)R^6$, C_{0-6} alkyl $NR^5(CO)NR^5R^6$, $O(CO)NR^5R^6$, C_{0-6} alkyl(SO_2) NR^5R^6 , OC_{2-6} alkyl(SO_2) NR^5R^6 , C_{0-6} alkyl $NR^5(SO_2)R^6$, OC_{2-6}

$_{6-alkyl}NR^5(SO_2)R^6$, SO_3R^5 , $C_{1-6}alkylNR^5(SO_2)NR^5R^6$, $OC_{2-6}alkyl(SO_2)R^5$, $C_{0-6}alkyl(SO_2)R^5$, $C_{0-6}alkyl(SO)R^5$, $OC_{2-6}alkyl(SO)R^5$ and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S;

R^5 and R^6 are independently selected from, H, $C_{1-6}alkyl$, $C_{3-7}cycloalkyl$ and aryl;

m is selected from 0, 1, 2, 3 or 4;

n is selected from 0, 1, 2, 3 or 4;

p is selected from 0, 1, 2, 3 or 4; and

a salt or hydrate thereof.

2. A compound according to claim 1 wherein X^7 is C.

3. A compound according to claim 1 wherein X^5 is selected from the group consisting of $CR^4R^{4'}$, NR^4 , O, S, SO and SO_2 .

4. A compound according to claim 1 wherein X^3 is selected from the group consisting of N and O.

5. A compound according to claim 1 wherein P is aryl.

6. A compound according to claim 5 wherein P is phenyl.

7. A compound according to claim 6 wherein m is selected from the group consisting of 1 and 2.

8. A compound according to claim 1 wherein R^1 is selected from the group consisting of: hydrogen, halo, $C_{1-6}alkylhalo$, $OC_{1-6}alkylhalo$, $C_{1-6}alkyl$, $OC_{1-6}alkyl$, $C_{1-6}alkylOR^5$, $C_{0-6}alkylcyano$, $C_{0-6}alkylNR^5R^6$.

9. A compound according to claim 8 wherein R^1 is selected from the group consisting of:

Cl, F, Me, OMe, CF₃, OCF₃, and CN.

10. A compound according to claim 1 wherein X² is C.

11. A compound according to claim 10 wherein X¹ is N or CR⁴.

12. A compound according to claim 11 wherein when X³ is O, X⁴ is N and when X³ is N, X⁴ is O.

13. A compound according to claims 1 wherein X² is N.

14. A compound according to claim 13 wherein X¹ is N.

15. A compound according to claim 14 wherein X³ is N and X⁴ is N or CR⁴.

16. A compound according to claim 1 wherein X⁶ is N.

17. A compound according to claim 1 wherein X⁵ is selected from the group consisting of CR⁴R^{4'}, NR⁴ and O.


18. A compound according to claim 12 wherein X⁵ is selected from the group consisting of O and NR⁴.

19. A compound according to claim 15 wherein X⁵ is CR⁴.


20. A compound according to claim 1 wherein R⁴ is selected from the group consisting of: hydrogen, C₁₋₆alkyl, C₁₋₆alkylhalo and halo.

21. A compound according to claim 1 wherein Q is heteroaryl.

22. A compound according to claim 1 wherein Q is selected from the group consisting of:



23. A compound according to claim 22 wherein Q is



24. A compound according to claim 1 wherein R^2 and R^3 are independently selected from the group consisting of: hydrogen, C_{1-4} alkylhalo, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{0-6} alkylaryl and C_{0-6} alkylheteroaryl.

25. A compound according to claim 1 wherein A is selected from the group consisting of: hydrogen, hydroxyl, halo, C_{0-6} alkylcyano, C_{1-6} alkyl, $-OC_{1-6}$ alkyl, C_{1-6} alkylhalo, OC_{1-6} alkylhalo.

26. A compound according to claim 1 selected from:

4-(5-{2-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-piperidin-1-yl}-4-methyl-4H [1,2,4]triazol-3-yl)-pyridine

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine

3-[5-(3-Chloro-phenyl)-isoxazol-3-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-morpholine

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine-1-carboxylic acid tert-butyl ester

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-methyl-1-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-piperazine

3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine-1-carboxylic acid tert-butyl ester

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine

2-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-1-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-4-methyl-piperazine

2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine

4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-[5-(4-methoxyphenyl)-4-methyl-4H-1,2,4-triazol-3-yl]piperidine

[4-(5-{2-[2-(3-chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)phenyl]dimethylamine

[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-1,2,4]triazol-3-yl)-benzyl]-dimethyl-amine

{2-[4-(5-{2-[2-(3-Chloro-phenyl)-2H-tetrazol-5-yl]-piperidin-1-yl}-4-methyl-4H-1,2,4]triazol-3-yl)-phenoxy]-ethyl}-dimethyl-amine

(R)-3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine

(S) 3-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-(4-methyl-5-pyridin-4-yl-4H-[1,2,4]triazol-3-yl)-morpholine

(R)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine

(S)-2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]-1-{5-[4-(difluoromethoxy)phenyl]-4-methyl-4H-1,2,4-triazol-3-yl}piperidine

(R)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine

(S)-4-(5-{2-[2-(3-Chlorophenyl)-2H-tetrazol-5-yl]piperidin-1-yl}-4-methyl-4H-1,2,4-

triazol-3-yl)pyridine

27. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1 to 26, in association with one or more pharmaceutically acceptable diluent, excipients and/or inert carrier.

28. The pharmaceutical composition according to claim 27, for use in the treatment of mGluR 5 mediated disorders.

29. The compound according to any one of claims 1 to 26, for use in therapy.

30. The compound according to any one of claims 1 to 26, for use in treatment of mGluR 5 mediated disorders.

31. Use of the compound according to any one of claims 1 to 26, in the manufacture of a medicament for the treatment of mGluR 5 mediated disorders.

32. A method of treatment of mGluR 5 mediated disorders, comprising administering to a mammal, including man in need of such treatment, a therapeutically effective amount of the compound according to any one of claims 1 to 26.

33. The method according to claim 32, for use in treatment of neurological disorders.

34. The method according to claim 32, for use in treatment of psychiatric disorders.

35. The method according to claim 32, for use in treatment of chronic and acute pain disorders.


36. The method according to claim 32, for use in treatment of gastrointestinal disorders.

37. A method for inhibiting activation of mGluR 5 receptors, comprising treating a cell

containing said receptor with an effective amount of the compound according to claim 1.

ABSTRACT

The present invention relates to new compounds of formula I,



(I)

wherein P, Q, X¹, X², X³, X⁴, X⁵, X⁶, R¹, R², R³, m, n, and p are as defined as in formula I, or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Application Data Sheet

Application Information

Application Type:: Provisional
Subject Matter:: Utility
Suggested classification::
Suggested Group Art Unit::
CD-ROM or CD-R?:: None
Computer Readable Form (CRF)?:: No
Title:: POLY-HETEROCYCLIC COMPOUNDS AND THEIR
USE AS METABOTROPIC GLUTAMATE RECEPTOR
ANTAGONISTS
Attorney Docket Number:: 085747-0325
Request for Early Publication?:: No
Request for Non-Publication?:: No
Suggested Drawing Figure::
Total Drawing Sheets::
Small Entity?:: No
Petition included?:: No
Secrecy Order in Parent Appl.?:: No
Applicant Information

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Jalaj
Family Name:: ARORA
City of Residence::
Country of Residence::
Street of mailing address::

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Louise
Family Name:: EDWARDS

City of Residence::
Country of Residence::
Street of mailing address::

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Methvin
Family Name:: ISAAC
City of Residence::
Country of Residence::
Street of mailing address::

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Annika
Family Name:: KERS
City of Residence::
Country of Residence::
Street of mailing address::

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Karin
Family Name:: OSCARSSON
City of Residence::
Country of Residence::
Street of mailing address::

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity

Given Name:: Abdelmalik
Family Name:: SLASSI
City of Residence::
Country of Residence::
Street of mailing address::

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Tomislaw
Family Name:: STAFANEC
City of Residence::
Country of Residence::
Street of mailing address::

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: David
Family Name:: WENSBO
City of Residence::
Country of Residence::
Street of mailing address::

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Tao
Family Name:: XIN
City of Residence::
Country of Residence::
Street of mailing address::

Correspondence Information

Correspondence Customer Number:: 22428

E-Mail address:: PTOMailWashington@Foley.com

Representative Information

Representative Customer Number::	22428	
---	-------	--

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::

Foreign Priority Information

Country::	Application number::	Filing Date::	Priority Claimed::

Assignee Information

Assignee name:: AstraZeneca and NPS Pharmaceuticals, Inc.